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Abstract 
 
Congenital Adrenal Hyperplasia (CAH) encompasses several disorders related to disruptions in 
the adrenal steroid production pathway. These disruptions may cause virilization of the external female 
sex organs, incorrect gender assignment, precocious puberty, and in the most severe form, may cause 
life-threatening salt wasting and adrenal crisis if not detected and treated early in the newborn period. 
17α-Hydroxyprogesterone (17-OHP) is the primary target for immunofluorescence detection of 
CAH from dried blood spots in newborn screening (NBS). Unfortunately, current immunoassay 
techniques for the detection of CAH suffer from high false positive rates. The primary factors 
contributing to false positive determinations can include the natural increase of 17-OHP due to stress 
stimuli as well as cross-reactivity of the immunoassay antibody with other hormones and endogenous 
compounds in blood.  
Analysis of the adrenal steroid profile and corresponding analyte ratios using high performance 
liquid chromatography (HPLC) or ultra-high pressure liquid chromatography (UHPLC) combined with 
tandem mass spectrometry (MS/MS) has been shown to be a sensitive and selective technique for the 
significant reduction of the false positive reporting rate for CAH in newborn screening. 
In working toward optimization, validation, and implementation of an HPLC-MS/MS steroid 
profile for use by Virginia’s Newborn Screening laboratory as a 2nd tier analysis for CAH screening, a 
commercially-available core-shell HPLC column with a biphenyl stationary phase was determined to 
offer adequate retention and selectivity to achieve baseline resolution of isobaric target analytes under 
rapid reversed phase gradient conditions. Method linearity, precision, and accuracy were assessed using 
enriched dried blood spot materials. Double-blinded analyses of over 300 newborn dried blood spot 
specimens were used to determine clinical sensitivity and specificity of the assay, which is projected to 
 xvi 
substantially reduce the false positive reporting rate for CAH screening while meeting target sample 
turnaround times. 
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CHAPTER 1: INTRODUCTION 
 
 
1.1 Newborn screening 
Newborn screening (NBS) is widely described as a public health success and owes its roots to Dr. 
Robert Guthrie, who, in the late 1950s, modified a bacterial growth inhibition assay to measure 
phenylalanine as a biochemical marker for detection of phenylketonuria (PKU).1,2 PKU is a devastating 
metabolic disorder causing an inability to metabolize the amino acid phenylalanine to tyrosine, which 
can lead to severe mental disabilities due to metabolic crisis if not detected and treated early. 3 By the 
early 1960s, Guthrie and Susi showed that the assay was well-suited for screening of large newborn 
populations using a dried blood spot matrix.1 In the years that followed, NBS for PKU was adopted by 
public health laboratories in all fifty states as well as many countries around the world.4 As additional 
disorders proved to be good candidates for screening and as analytical technologies advanced, NBS 
expanded to encompass dozens of disorders. The main mission of NBS is to utilize population-wide 
screening of all infants in order to offer the best chance of identifying rare inherited disorders as early as 
possible, ideally before the onset of symptoms. This early detection offers the best possibility for 
immediate intervention and improved outcomes. 
 Most NBS tests continue to utilize the dried blood spot (DBS) matrix, which involves dropping 
capillary blood, usually from a heel stick of the infant, onto specialized filter paper and allowing the 
blood to dry. Samples are ideally collected when the newborn is between one and two days old, 
allowing enough time for biomarkers to build up in the blood of individuals affected by the disorders, 
but not waiting so long as to significantly delay testing.5,6 The DBS sample is minimally invasive to collect 
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and is easy to package and transport to the testing laboratory, whether by commercial carrier or courier 
service. Once at the laboratory, paper punches containing dried blood are removed from the blood 
spots for analysis.  
 As the number of candidate disorders for NBS grew, various analytical technologies were 
adopted by screening laboratories to accommodate testing. Screening methodologies are ideally rapid, 
economical, and have adequate sensitivity to differentiate affected individuals from the normal 
population. Beyond bacterial growth inhibition assays, one of the earliest technologies adopted for NBS 
was the immunoassay. 7 During the 1990s and early 2000s, flow injection analysis-electrospray 
ionization-tandem mass spectrometry began being incorporated by NBS laboratories as a method to 
rapidly screen for several metabolic disorders simultaneously from a single blood spot punch.4,8  
 While NBS was eventually adopted by all fifty states, there were often wide inconsistencies 
between states regarding which conditions were screened and timelines for implementation. In the 
early 2000s, in an effort to solidify national guidelines regarding exactly which conditions should be the 
primary targets for newborn screening, an expert panel from the American College of Medical Genetics 
(ACMG) provided the Recommended Uniform Screening Panel (RUSP) of primary and secondary 
conditions as top candidates for mandated universal NBS.9 The original recommended panel included 29 
core disorders and 25 secondary disorders. The process also established evaluation criteria of data 
related to screening methodologies, costs, possible treatments, and outcomes related to universal 
screening for consideration of future candidate disorders for inclusion on the RUSP. The current RUSP, 
now evaluated and maintained by the Secretary’s Advisory Committee on Heritable Disorders in 
Newborns and Children (SACHDNC) under the Secretary of Health and Human Services, contains 35 core 
disorders and 26 secondary disorders.10  
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 Many of the disorders commonly targeted by NBS involve reduced or eliminated function of 
enzymes. 3,5,11 The two most common biochemical approaches to screen for deficient enzyme activity 
involve direct or indirect analysis. In direct analysis, enzyme activity is measured, usually through 
interaction with a specific enzyme substrate to produce a reaction target that is then measured by the 
assay. The amount of target produced over a specific time period allows for calculation of enzyme 
activity rate. The indirect approach involves detection and quantitation of biomarkers, usually the 
buildup of precursors, proximal to the target enzyme.  
 NBS laboratories, in consultation with medical specialists or advisory committees, continually 
strive to reach a balance in trying to hone methods and cutoffs to avoid missing individuals affected by a 
disorder with maintaining the lowest possible false positive rate. False positive results occur when the 
analytical result for a specimen falls outside of the anticipated normal range for a given analyte, 
prompting collection of another specimen or referral for diagnostic testing, when the individual is not 
affected with the disorder. While less detrimental than a missed diagnosis, false positive results can 
cause a myriad of issues within the NBS system as well as to families that are impacted by the screening 
results. False positive results may cause added stress to new parents as they worry whether their child 
has a potentially serious condition and face the added costs associated with diagnostic testing. False 
positives may add stress and caseload to medical specialists tasked with clinical follow-up of babies 
identified through screening. Reporting a high number of false positives may also diminish confidence in 
the overall validity of the screening assay as a complacency may develop among physicians that receive 
many reports of positive screening results that rarely, if ever, pan out to be a true diagnosed case. False 
positives also strain NBS laboratories and follow-up programs as they create more samples for the 
laboratory to run as well as more cases that must be tracked within the follow-up system. 12–14 
Congenital adrenal hyperplasia (CAH) is among the core RUSP disorders screened by all US 
states and territories.10,15 Primary screening methods for CAH rely on immunoassays targeting a single 
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biomarker, 17α-hydroxyprogesterone (17-OHP). 5,7,16 Immunoassays screening for elevated levels of 17-
OHP suffer from high false positive rates, often 1-3 %, even when assay cutoffs are adjusted to correct 
for common influential factors such as low birth weight or gestational age.17,18 17-OHP becomes 
elevated under times of increased stress, as is often the case with severely premature, low birth weight, 
or sick newborns. Adrenal immaturity may also play a role in elevation of 17-OHP.18,19 Additionally, 
immunoassay antibodies for 17-OHP show cross reactivity for other endogenous steroids and 
precursors, some of which are at much higher concentrations in the blood stream than 17-OHP.20 All of 
these factors contribute to high false positive rates for CAH screening based on immunoassays targeting 
17-OHP. 
  
1.2 Congenital adrenal hyperplasia 
1.2.1. Steroidogenesis in the adrenal glands 
 
 Glucocorticoid and mineralocorticoid steroid production in the adrenal glands is regulated by 
adrenocorticotropic hormone (ACTH) produced in the pituitary gland of the brain.11 Under normal 
function, production of the glucocorticoid cortisol serves as a feedback loop to the process. Steroids are 
synthesized from cholesterol via a series of cleavage, dehydrogenation, and hydroxylation reactions 
facilitated by five enzymes. As indicated in Figure 1, the production of the glucocorticoid cortisol 
involves side chain cleavage of cholesterol between carbons 20 and 22 to form pregnenolone. Next, 
pregnenolone is hydroxylated at carbon 17 by 17α-hydroxylase to form 17α-hydroxypregnenolone. 
Dehydrogenation of oxygen at carbon 3 by 3β-hydroxysteroid dehydrogenase (3β-HSD) yields 17-OHP. 
17-OHP is then further hydroxylated by 21-hydroxylase to form 11-deoxycortisol (11-DOC). Finally, 11-
DOC is hydroxylated by 11β-hydroxylase to form cortisol.21 
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Figure 1. Schematic of human steroidogenesis, Reprinted from WikiJournal of Medicine 2014 – Congenital adrenal hyperplasia, 
Retrieved September 25, 2019, from 
https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia#/media/File:Steroidogenesis.svg. Reformatted to include red 
boxes around enzymes associated with congenital adrenal hyperplasia under Creative Commons License CC BY-SA 3.0. 
  
In addition to the biosynthesis pathways depicted in Figure 1, an additional steroid, 21-
deoxycortisol (21-DOC) may be produced by hydroxylation of excess 17-OHP by 11β-hydroxylase when 
21-hydroxylase activity is reduced or absent, as depicted in Figure 2.22 
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Figure 2. Schematic of enzymatic hydroxylation of 17-OHP to 21-DOC via 11β-hydroxylase in the absence of residual 21-
hydroxylase function. 
 
1.2.2. Pathophysiology 
 
 CAH is a group of disorders caused by genetic mutations leading to reduced or eliminated 
activity of one of the five enzymes along the glucocorticoid and mineralocorticoid production pathway in 
the adrenal glands, outlined in red in Figure 1.11,21 The most common cause of CAH is deficiency of the 
21-hydroxylase enzyme which is responsible for approximately 90-95 % of CAH cases.11,16,23  Because 21-
hydroxylase deficiency is far more common than other forms of CAH, there is strong justification for 
selecting the precursor to the 21-hydroxylase enzyme, 17-OHP, as the primary target for newborn 
screening assays. CAH is characterized into classic and non-classic forms. Classic forms of CAH are the 
most severe, and often present with symptoms at birth such as in-utero virilization of external genitals 
which may even lead to incorrect gender assignment of severely virilized females at birth. Classic CAH is 
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also characterized by low cortisol production relative to elevated levels of steroid precursors and 
androgens within the blood.  If untreated, classic forms of CAH may also lead to precocious puberty, 
accelerated skeletal aging, and shortened adult stature. Classic CAH is further subdivided into two 
forms: salt-wasting and simple virilizing. The most severe, salt-wasting form of CAH accounts for 
between two-thirds to three-quarters of classic CAH cases, while simple virilizing CAH accounts for the 
remaining quarter to one-third of cases. Salt-wasting CAH may cause life-threatening shock, 
dehydration, and adrenal crisis within the first days or weeks of life.23 Simple virilizing CAH has moderate 
severity, as it can be associated with significant androgen production and therefore virilization of the 
external genitals, however it does not cause salt-wasting crisis. Incidence rates for classic CAH are 
reported to be between 1:12,000 to 1:15,000 live births but can show wide variability among certain 
subpopulations.16,23 Non-classic CAH shows a later age at onset and is often diagnosed after the 
newborn period and may lead to precocious puberty, accelerated skeletal aging, and shortened stature. 
Some cases of non-classic CAH do not require treatment. Up to 5 % of CAH cases are caused by 
deficiencies in enzymes other than 21-hydroxylase, the most common being 11β -hydroxylase.23  
1.2.3. Treatment 
 
Treatments for CAH can involve life-long administration of glucocorticoids and 
mineralocorticoids to replace deficient cortisol and aldosterone and to reduce androgen production. Salt 
supplementation may also be necessary for patients with the salt wasting form of classic CAH.16,23 
Severely virilized females may undergo reconstructive surgery of the external genitals.24,25 
1.2.4. Primary methodology for newborn screening 
 
Currently, the Virginia NBS laboratory screens DBS specimens from all babies born in the 
Commonwealth for CAH utilizing a solid phase time-resolved fluorescence immunoassay method on the 
PerkinElmer Genetic Screening Processor (GSP™) targeting 17-OHP.26 As indicated in Figure 3, the assay 
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works by competitive binding between sample 17-OHP and europium-labeled 17-OHP with rabbit 17-
OHP antibodies in solution. The rabbit 17-OHP antibodies are bound to antibodies fixed to the walls of 
the well plate. After washing away unbound material, a dissociation-enhanced lanthanide fluorescence 
immunoassay (DELFIA) inducer is added to cleave the europium ions from the labeled 17-OHP 
molecules. The DELFIA inducer forms a fluorescent chelate with the freed europium molecules in 
solution and this fluorescence is measured.27 The measured fluorescence signal is inversely proportional 
to 17-OHP concentration within the sample.26,27 
 
Figure 3. Representative schematic of competitive binding fluorescence immunoassay. Adapted from 
https://www.perkinelmer.com/lab-products-and-services/application-support-knowledgebase/delfia/delfia-trf-assays.html 
 
 When using only the immunoassay method for CAH screening, the NBS laboratory employs 
replicate DBS analysis and birthweight-adjusted cutoffs for interpretation of CAH screening results. A 
single initial DBS punch is analyzed from each DBS specimen received by the laboratory using the 
immunoassay targeting 17-OHP. Any specimen showing 17-OHP greater than or equal to 20 ng/mL 
serum (or the top 3% of specimens from analysis of each 96 well plate, whichever number of specimens 
is greater) is repeated by the immunoassay using duplicate DBS punches from the same DBS specimen. 
All specimens that do not require replicate analysis are reported as within normal limits for the CAH 
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screening test. For samples requiring replicate analysis, 17-OHP concentration results are compared to 
the birthweight-adjusted cutoffs depicted in Table 1. Due to stress related elevations of 17-OHP in the 
premature population, low birthweight newborns have the highest relative 17-OHP cutoffs as compared 
with higher birthweight newborns. Upon comparison to birthweight-adjusted 17-OHP cutoffs, a 
determination is made for each DBS specimen to indicate whether the results were reported as within 
normal limits, abnormal, or critical. Results reported as within normal limits do not require additional 
testing or interventions. Abnormal results trigger the request for a repeat DBS specimen to be drawn 
from the infant and returned to the NBS laboratory as soon as possible for confirmatory testing. Critical 
results require immediate referral of the infant to the Virginia Department of Health NBS follow-up 
team and requests for the primary care physician to consult with a pediatric endocrinologist as well as to 
order diagnostic tests to determine if CAH is present. 
Table 1. Birthweight-adjusted 17-OHP cutoffs employed when using the immunoassay alone for CAH screening. 
Birthweight Category Normal 17-OHP (ng/mL serum) 
Abnormal 17-OHP 
(ng/mL serum) 
Critical 17-OHP 
(ng/mL serum) 
< 1250 g < 55 > 55 & < 65 > 65 
1250 – 1749 g < 40 > 40 & < 60 > 60 
1750 – 2249 g < 35 > 35 & < 45 > 45 
> 2250 g < 25 > 25 & < 45 > 45 
 
 
1.2.5. Issue with primary screening methodology 
 
Due to natural, stress-related, elevations of 17-OHP in newborns caused by prematurity, low 
birth weight or illness, as well as cross-reactivity of the immunoassay antibodies with interfering 
compounds, a disproportionately high number of false positive results are reported.28–33 Adjusting assay 
cutoff algorithms to include consideration of factors such as birth weight or gestational age are 
commonly used and have been shown to reduce false positive reporting rates based upon 17-OHP 
 10 
immunoassay screening, especially among severely premature or low birth weight infants 17, however, 
false positive rates still remain high relative to many other NBS assays.  
1.2.6. Need for 2nd tier analysis 
 
Supplemental 2nd tier analyses of dried blood spot specimens have been shown to reduce false 
positive rates for CAH in newborn screening programs.28–33 Second tier assays involve performing 
additional analysis using the same DBS specimen, without the need to request additional samples. 
Though sometimes more expensive or time-consuming than 1st tier analyses, 2nd tier assays are often 
employed to offer improved specificity over 1st tier methods.12 2nd tier biochemical screening for CAH 
involves detection and quantitation of multiple analytes along the adrenal steroidogenesis pathway. By 
accurately quantitating cortisol along with steroid precursors and androgen, the screening laboratory is 
able to establish a more comprehensive evaluation of the enzyme function within the adrenal glands 
and ratios may be used to better differentiate affected cases of CAH, where cortisol production will 
often be significantly reduced, from unaffected individuals with elevated concentration of steroid 
precursor unrelated to CAH. 
Table 2 depicts concentration ranges for cortisol, steroid precursors, and androstenedione 
within blood specimens from newborns and infants unaffected by CAH reported to the Human 
Metabolome Database.34 References are for human blood and do not necessarily represent analysis of 
dried blood spots.  
Table 2. Blood concentration ranges of cortisol and steroid precursors within newborns and infants unaffected by CAH reported 
to the Human Metabolome Database.34 
Analyte Concentration range in unaffected newborns and infants (ng/mL serum) 
17-OHP 0.14 – 30 
21-DOC 0.69 – 5.5 
11-DOC < 42 
4-AD 0.40 – 8.0 
CORT 9.4 – 1200 
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1.3 LC-MS/MS methods for 2nd tier CAH screening 
1.3.1. Reported approaches 
 
 The most frequent reports of methodologies employed for 2nd tier CAH analysis in newborn 
screening involve liquid chromatography with detection by tandem mass spectrometry. Most NBS 
laboratories are familiar with tandem mass spectrometers as they are commonly utilized to 
accommodate routine screening for amino acid and acylcarnitine indicators of various metabolic 
disorders, usually via flow injection analysis (FIA).4,8 If redundant instrumentation is available, the ability 
to perform 2nd tier analysis may be possible with slight modifications to existing equipment in order to 
incorporate liquid chromatography into the analysis. Earlier reported alternatives for detection and 
quantification of a panel of steroids for CAH diagnosis involve analysis by gas chromatography-mass 
spectrometry (GC-MS).35–37 GC-MS methods offer improved specificity over immunoassays, however 
they often involve complicated sample preparation or derivatization steps as well as longer analysis 
times, making GC-MS assays less than ideal for high throughput NBS laboratories.  
 In 2004, Lacey et al. reported a 2nd tier screening assay for CAH that utilized high performance 
liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) for the detection and 
quantification of 17-OHP, androstenedione (4-AD), and cortisol from NBS dried blood spots.28 The assay 
utilized a 4.8 mm DBS punch and aqueous elution of the blood followed by repeated liquid-liquid 
extraction using diethyl ether. The extracts were then dried and reconstituted in solvent phase 
appropriate for reversed phase HPLC. The chromatographic program utilized reversed phase gradient 
separations on a C18 column. The gradient profile was 12 min long in order to fully elute a compound 
released by the filter paper matrix. The assay used a single internal standard, stable isotope-labeled 17-
OHP-D8. In addition to determination of 17-OHP concentrations, the authors reported that an additional 
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metric involving calculation of the ratio of the sum of peak areas for 17-OHP plus 4-AD divided by the 
peak area for cortisol offered added specificity to further reduce false positive results.  
 In 2007, Janzen et al. from the NBS program in Hanover, Germany, reported an HPLC-MS/MS 
assay for DBS screening that targeted an expanded panel of steroid markers, including 21-DOC and 11-
DOC with a rapid 6 min analysis time per injection.30 Their use of a 20 mm length C18 HPLC column 
allowed for a short gradient profile. In 2008 the same group reported an expansion of the assay to 
include quantitation of testosterone and dihydrotestosterone, which are not typically produced in 
significant amounts within the adrenal glands but are more commonly produced in the gonads. 31,38 They 
reported the use of two stable isotope-labeled internal standards, 17-OHP-D8 and cortisol-D2. The 
authors reported an algorithm that utilized 21-DOC as the primary marker for detection of CAH due to 
21-hydroxylase deficiency, however, other reports suggest that 21-DOC may not always elevate in the 
absence of significant ACTH stimulation and therefore may not be detected in all cases.39,40 It is 
therefore recommended that 21-DOC be used as a secondary marker for CAH screening. By targeting 11-
DOC within the assay, the same group reported detection of rare cases of CAH due to 11β-hydroxylase 
deficiency through newborn screening. 
 In 2011, the California NBS program reported an HPLC-MS/MS assay for 2nd tier screening of 
CAH using a C18 column with an approximate 8.5 min analysis time per injection.29  The assay was 
optimized for detection and quantitation of 17-OHP, 4-AD, cortisol, and secondary analytes 21-DOC and 
11-DOC. The inclusion of secondary analytes with the screening algorithm was reported to reduce the 
impact of the 2nd tier assay by maintaining too many false positive results for CAH screening. 
 Multiple publications report the use of ultra-high performance liquid chromatography (UHPLC) 
pumps and columns with sub-2 µm silica particles for the stationary phase support.32,41 This setup may 
allow for more rapid and efficient separations than standard HPLC, but can come at an additional cost 
 13 
for specialized equipment. In 2008, ARUP® Laboratories, in collaboration with the Utah NBS program, 
reported a 2nd tier CAH screening assay utilizing UHPLC reversed phase separations on a C18 column at a 
run time of approximately 4 min per injection.32 The Utah report also established the use of a 2nd tier 
CAH algorithm cutoff based solely on elevated clinical ratio. This was due to results from a prospective 
study wherein the DBS sample from one newborn affected by CAH showed a 17-OHP concentration 
within normal limits by the 2nd tier screening assay, however showed a highly elevated clinical ratio. This 
particular infant had received corticosteroid treatment to combat breathing issues prior to collection of 
the DBS specimen, possibly leading to reduced levels of 17-OHP. The use of a separate cutoff defined 
solely by the clinical ratio of concentrations of 17-OHP and 4-AD relative to cortisol is reported to serve 
as a safeguard in order to detect cases of individuals with CAH whose analyte profiles might be masked 
by receiving corticosteroid treatment prior to collection. The Utah study also reported use of stable 
isotope-labeled internal standards for each target compound, which is reported to improve precision 
and accuracy of calculated concentrations.33  
 In 2015, an LC-MS/MS assay of steroids from DBS was reportedly used to study reference ranges 
within the population of South Korea.42 They reported use of a C18 stationary phase ligand on a 
superficially porous (core-shell) stationary phase support. The assay was able to achieve separation of 
seven steroids, including isobaric species, however the analysis time was reported at 20 min per 
injection. 
 Biphenyl stationary phase ligands have been reported to show improved separation of various 
steroids, including isobaric species.43 While serum diagnostic assays have been reported, no reports 
using biphenyl stationary phase ligand for DBS analysis in NBS were found.  
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1.3.2. Chromatographic resolution of isobars 
 
 Chromatographic separation is often necessary when attempting to accurately quantitate 
isobaric compounds in biochemical analysis using detection by tandem mass spectrometry. Isobars are 
molecules with the same molecular weight but different structure. If the molecules share the same 
precursor mass-to-charge ratio (m/z), but significantly differ either in structure or constituent atoms, 
differentiation by MS/MS experiments may still be possible if a product ion specific to each isobar is able 
to be isolated and detected. Isobars that share a precursor m/z and also fragment to similar product 
ions are not able to be differentiated by the mass spectrometer and must first be resolved into distinct 
analyte bands on-column so they reach the ionization source at different times.  
 In the case of molecules related to steroidogenesis in the adrenal glands, several isobaric 
compounds are constitutional isomers that share similar structure, varied only in the positioning of 
hydroxy groups. In positive electrospray ionization mode, 17-OHP and deoxycorticosterone share the 
same precursor m/z of 331. These species are usually easily resolved chromatographically. For LC-
MS/MS assays that target only 17-OHP, 4-AD, and cortisol, isobaric interferences are not typically of 
issue. Expanded assays that target 21-DOC or 11-DOC pose a more difficult challenge. 21-DOC, 11-DOC, 
and another molecule, corticosterone share the same precursor m/z of 347. These three isobars are 
often more difficult to resolve chromatographically. Some of the reported assays offer poor resolution 
of isobars.30,31 Others employ ultra-high performance liquid chromatography (UHPLC) or longer HPLC 
gradients to adequately resolve isobars. 28,29,32,41,42 Additionally, some of the assays reporting separation 
and quantitation of 21-DOC and 11-DOC make no mention of corticosterone, which has been shown to 
elute between 21-DOC and 11-DOC during separations on C18 columns. Columns based on a biphenyl 
stationary phase ligand have been shown to efficiently separate steroids from plasma matrix,43 but have 
not been reported as being utilized in NBS 2nd tier assays of DBS.  
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1.3.3. Reduction of false positive results 
 
 The main impact of 2nd tier CAH screening is reduction of false positive NBS reporting. False 
positive results may cause undue burden on the newborns and their families, the healthcare system, 
and the NBS system. An overabundance of false positive results may also lead to reduced credibility of 
screening results. Primary screening assays for CAH only target one molecule, 17-OHP. Immunoassays 
targeting 17-OHP show cross reactivity for other endogenous compounds commonly found, often at 
much higher concentrations, in biological matrices. Additionally, 17-OHP is significantly elevated when 
newborns experience stress due to illness, prematurity, or prolonged delivery. LC-MS/MS 2nd tier 
analysis offers improved specificity by providing a more comprehensive evaluation of the enzyme 
system impacted by CAH. 2nd tier LC-MS/MS assays for CAH offer a more specific quantitative value of 
17-OHP concentration by differentiating the molecule from endogenous interferences. Quantitation of 
molecules downstream of the enzymes most often affected by CAH allows for determination of healthy 
adrenal function relative to true cases of CAH. 
1.3.4. Challenges of reported approaches 
 
 Some of the reported studies note false negative results. Of greatest concern are false negative 
results for salt-wasting or simple virilizing cases. Many of the missed cases are attributable to the 1st tier 
17-OHP results for the DBS specimen failing to cross analyte cutoffs that trigger 2nd tier analysis. Most 
2nd tier assays screening for CAH take into account clinical ratios of precursor analytes such as 17-OHP, 
4-AD, or 21-DOC relative to the final product of enzymatic steroidogenesis, cortisol, to aid in 
differentiation between affected individuals and individuals with normal enzyme function. Cases missed 
by 2nd tier analysis often show elevated results for 17-OHP but do not show an elevated ratio of 
precursor analytes relative to cortisol concentration and therefore were not reported as abnormal. In 
cases of moderate or mild forms of CAH, enough residual enzyme activity may be present to generate 
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enough cortisol to push ratios lower, resulting in a false negative interpretation. NBS programs must 
continually look retrospectively at cases successfully diagnosed based on screening algorithms as well as 
any cases missed by the screening algorithm in order to refine cutoffs or processes to ensure the best 
possible outcomes. Non-classic CAH is thought to have a much higher prevalence than classic CAH, with 
some estimates above 1% in some populations, but typically does not result in virilization at birth and is 
not reliably detected by NBS. Second tier analysis is not anticipated to improve detection rates for non-
classic CAH and may, in fact, rule out as normal some cases of non-classic CAH detected by elevated 17-
OHP levels alone. Other challenges to reported 2nd tier assays include poor resolution of isobars or long 
HPLC gradient runs in order to achieve adequate resolution of target compounds. 
1.3.5. Importance of timeliness in CAH screening 
 
 The most severe, salt-wasting form of CAH can lead to life-threatening adrenal crisis as early as 
the first few weeks of life. It is therefore imperative that newborn screening for CAH occur quickly. This 
is especially important for identification of males with CAH, as there may be no physical symptoms of 
CAH evident at birth, whereas virilized females will present with ambiguous genitalia at birth. CAH is 
among the NBS conditions considered to be time-critical. Current national timeliness guidelines 
recommend that all NBS programs aim to report presumptive positive results for time-critical NBS 
conditions at no later than five days of life.6 This gives the greatest opportunity to get newborns under 
care and treatment before the onset of life-threatening symptoms. To achieve this goal, emphasis is 
placed on timely collection of NBS specimens, rapid and reliable transport to the testing laboratory, and 
that screening methods and algorithms occur with as little delay as possible while maintaining high-
quality results. 
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1.4 Project goals 
 
 The primary objectives for this work were development of a 2nd tier CAH screening assay using 
HPLC-MS/MS and validation of the method for implementation within Virginia’s NBS laboratory. The 
validated assay should utilize existing instrumentation available within the laboratory with minimal 
modifications, should offer acceptable sensitivity for the most severe forms of CAH while greatly 
reducing false positive reporting, and should offer rapid throughput to enable timely reporting of 
results. Another aim of this work was to improve upon reported HPLC conditions to achieve baseline 
resolution of isobaric interferences while maintaining a rapid chromatographic separation. 
 Several steps were involved in the systematic optimization of the method and subsequent 
validation. First, electrospray ionization and fragmentation parameters in the tandem mass 
spectrometer were optimized for each target compound, each stable isotope-labeled internal standard, 
as well as know isobaric interferences. Next, chromatographic conditions were optimized to select 
stationary phase ligand and gradient conditions. HPLC column temperature settings were also 
optimized. Next, DBS extraction and sample preparation conditions were optimized to ensure adequate 
sensitivity and reproducibility. Finally, matrix-matched DBS calibration, quality control, and method 
validation materials were produced. Following optimization, method validation experiments were 
conducted to provide documented evidence that the assay would consistently provide accurate data 
when placed into full production. 
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CHAPTER 2: METHOD DEVELOPMENT 
 
 
 
 Method development experiments followed a systematic approach for obtaining optimal 
instrument parameters for analysis of dried blood spots for targeted steroid markers. The primary goals 
of the method development process were to utilize existing instrumentation within the NBS laboratory 
with minimal modifications and to achieve a rapid analysis time that would accommodate a high 
throughput workflow while maintaining acceptable sensitivity for target compounds and optimal 
separation of known isobaric interferences. 
 
2.1 MS/MS compound optimization using direct infusion 
 
 Direct infusion experiments were performed using a syringe pump set to a flow rate of 10 
µL/min. The infusion syringe was connected directly to the electrospray ionization source via a length of 
PEEK tubing. 
2.1.1. Infusion stock preparation 
 
 Analytical standards of 17-OHP, cortisol, 4-AD, 11-DOC, and corticosterone, each at 1.0 mg/mL, 
were diluted to 1.0 µg/mL in methanol as intermediate stocks.  Each intermediate stock was further 
diluted to 200 ng/mL in 50:50 methanol: water with 0.1% formic acid to produce individual infusion 
standards. 
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 Analytical standards of 21-DOC, deoxycorticosterone, cortisol-D4, 17-OHP-D8, 21-DOC-D8, and 
11-DOC-D5, each at 100 µg/mL in methanol, were diluted to 200 ng/mL in 50:50 methanol: water with 
0.1% formic acid to produce individual infusion standards. 
 An analytical standard of 4-AD-13C3 at 100 µg/mL acetonitrile was diluted to 200 ng/mL in 50:50 
methanol: water with 0.1% formic acid to produce an individual infusion standard. 
2.1.2. Precursor ion isolation 
 
 A Sciex API 4000 (Framingham, MA, USA) triple quadrupole mass spectrometer equipped with 
an electrospray ionization source was utilized for all mass spectrometry experiments. To isolate the 
precursor ion for each analyte and internal standard, each 200 ng/mL infusion standard was individually 
introduced into the electrospray ionization source in positive ionization mode using the same ionization 
parameters: electrospray (ES) voltage 5500 V, nebulizer gas (GS1) 19 arbitrary units, declustering 
potential (DP) 60 V, entrance potential (EP) 10 V.  Scanning only quadrupole 1 (Q1), the [M+H]+ 
precursor ion mass-to-charge ratio (m/z) was isolated for 10 Multi Channel Analysis (MCA) events. 
Precursor ions for each analyte are noted in Table 3, and structures are depicted in Figure 4.  
Table 3. Precursor ions 
Analyte Precursor ion (m/z) 
4-AD 287.1 
4-AD-13C3 290.2 
17-OHP 331.3 
17-OHP-D8 339.2 
Deoxycorticosterone 331.3 
21-DOC 347.1 
21-DOC-D8 355.2 
11-DOC 347.1 
11-DOC-D5 352.1 
Corticosterone 347.3 
Cortisol 363.1 
Cortisol-D4 367.1 
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Figure 4. Chemical structures of target analytes and isobaric interferences. 
 
 
2.1.3. Product ion scanning 
 
 Following isolation of precursor ions using Q1 scans in positive ion mode, a product ion profile 
was identified for each analyte using the product ion scan function. Each 200 ng/mL infusion standard 
was individually introduced into the electrospray ionization source in positive ionization mode using the 
same ionization parameters: electrospray (ES) voltage 5500 V, nebulizer gas (GS1) 19 arbitrary units, 
declustering potential (DP) 60 V, entrance potential (EP) 10 V, collision energy (CE) 25 V, collision cell 
exit potential (CXP) 7 V. In product ion scan mode, the precursor ion for each analyte was entered for 
isolation in Q1 and fragmentation in the collision cell (Q2). Q3 was then scanned over a large mass range 
4-AD 17-OHP Deoxycorticosterone
21-DOC 11-DOC Corticosterone
CORT
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to allow for detection of possible product ion m/z values. The four to six most abundant product ions for 
each analyte, indicated in Table 4 were selected for further compound optimization. 
 
Table 4. Most abundant product ions 
Analyte Product Ions (m/z) 
4-AD 97.0, 109.0, 251.0, 269.1 
4-AD-13C3 100.0, 112.0, 126.0, 271.9 
17-OHP 97.0, 109.0, 295.1, 313.0 
17-OHP-D8 100.0, 113.2, 175.1, 321.0 
Deoxycorticosterone 97.1, 109.2, 295.1, 313.2 
21-DOC 121.1, 175.1, 269.2, 311.1, 329.1 
21-DOC-D8 125.0, 180.1, 275.1, 319.0 
11-DOC 97.0, 109.0, 328.9, 311.0, 299.0 
11-DOC-D5 100.0, 112.8, 316.2, 334.1 
Corticosterone 96.9, 120.8, 135.0, 293.0, 311.0, 329.2 
Cortisol 96.8, 120.9, 267.0, 309.0, 326.9 
Cortisol-D4 121.0, 313.2, 330.9, 349.2 
 
 Additionally, a more comprehensive study of product ions was initiated for isobaric compounds 
to determine if any unique product ions might be identified for each compound to aid with 
differentiation by the mass spectrometer alone. 11-DOC, 21-DOC, corticosterone, 17-OHP, and 
deoxycorticosterone were evaluated using product ion scans at collision energies between 5 V and 50 V 
at 5 V intervals. The product ion profiles for 11-DOC, 21-DOC, and corticosterone were compared to 
determine if any unique product ions were observed. Figure 5 shows representative product ion scans 
for 11-DOC, 21-DOC, and corticosterone at collision energy of 25 V. The isolated precursor mass-to-
charge ratio was 347 m/z for all three compounds. Similarly, the product ion profiles for 17-OHP and 
deoxycorticosterone were compared. No unique product ions at sufficient abundance for quantitation 
were identified, reinforcing the need to achieve baseline chromatographic resolution of isobars prior to 
detection by mass spectrometry. 
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Figure 5. Representative product ion spectra of isobaric compounds. Isolated precursor ion = 347 m/z. Collision energy = 25 V. 
 
2.1.4. Compound optimization 
 
 Isolation and fragmentation conditions of potential target product ions identified for each 
analyte, listed in Table 4, were further optimized using compound optimization features within the 
instrument software. The isolation and fragmentation parameters that were optimized for each ion 
transition were declustering potential (DP), collision energy (CE), and collision cell exit potential (CXP). 
For each analyte, a standard solution at 200 ng/mL concentration was directly infused into the 
electrospray source using a syringe pump. The precursor-to-product ion transitions specific to that 
analyte were entered into the software. The software then systematically ramped through each 
parameter, selecting as optimal the parameter setting that yielded the greatest detector signal for the 
ion transition. This process was repeated for all analytes and internal standards for all candidate ion 
transitions. Results of the compound optimizations were used when assigning multiple reaction 
monitoring (MRM) parameters for the full instrument acquisition method, explained in Chapter 3. 
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2.2 Electrospray ionization source parameter optimization using flow injection analysis 
 
 Electrospray ionization source parameter optimization was used to determine optimal 
electrospray source settings that were not compound specific and was performed using flow injection 
analysis (FIA) features within the instrument software compound optimization environment. An 
acquisition method incorporating optimized MRM parameters for each target analyte, internal standard, 
and potential isobaric interference was created and a short (1 min) isocratic HPLC run at 500 µl/min flow 
rate was added to the method parameters. The autosampler was set to load 5 µL into the injection loop 
for each injection. In FIA, a small volume of sample was introduced into a flow of mobile phase before 
moving directly to the electrospray ionization source, without separation on-column. The standard used 
for FIA optimization was made by mixing equal volumes of the 200 ng/mL infusion standards for each 
analyte, internal standard, and isobaric interference, yielding a final concentration for all compounds of 
16.7 ng/mL in 50:50 methanol: water with 0.1% formic acid. With each injection in the FIA experiment, 
the setting for a single source parameter is changed. Each parameter setting was analyzed in duplicate 
and results for all ion transitions were compared to assess which set point for each parameter yielded 
the greatest overall signal across all analyte transitions. Source parameters that were optimized include: 
electrospray voltage, nebulizer gas (GS1), heater gas (GS2), desolvation temperature, and curtain gas. 
The setpoints tested for each parameter are summarized in Table 5. The collision assisted dissociation 
(CAD) gas parameter was set to 6 for all experiments. 
Table 5. Electrospray ionization source parameter optimization FIA test points 
Parameter Test Points 
Electrospray positive voltage (V) 5500, 5000, 4500, 4000 
GS1 (arbitrary units) 50, 45, 40, 35 
GS2 (arbitrary units) 40, 35, 30, 25 
Desolvation temperature (°C) 550, 500, 450, 400 
Curtain gas (arbitrary units) 45, 40, 35, 30 
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 FIA source parameter optimization was performed using two mobile phase constituents. Mobile 
phase A was water with 0.1% formic acid. Mobile phase B was methanol with 0.1% formic acid. FIA 
experiments were originally performed with isocratic mobile phase settings at 70% B and were then 
later repeated with isocratic mobile phase settings at 50% B. Optimized source parameter settings at 
each isocratic mobile phase formulation are summarized in Table 6. Because early chromatographic 
optimization experiments with C18 stationary phase ligand indicated that the earliest eluting target 
compounds would elute near 50% B, optimized source parameters at 50% B mobile phase conditions 
were carried through remaining experiments. 
Table 6. Optimized electrospray ionization parameters from FIA experiments 
Parameter 70% B 50% B 
Electrospray positive voltage (V) 5000 4000 
GS1 (arbitrary units) 40 45 
GS2 (arbitrary units) 40 40 
Desolvation temperature (°C) 500 550 
Curtain gas (arbitrary units) 35 45 
 
 
2.3 Chromatographic optimization 
 
 Among the goals for development of an LC-MS/MS assay for 2nd tier screening of CAH were to 
utilize existing instrumentation within the laboratory, making as few modifications as possible, and to 
achieve an analysis run time that would accommodate high-throughput analysis and the most rapid 
possible turnaround times. Existing instrumentation within the newborn screening laboratory included 
Prominence LC-20AD pumps (Shimadzu, Kyoto, Japan), which have a maximum pressure limit of 400 bar 
(5801 psi). While ultra-high pressure liquid chromatography (UHPLC) has been shown to effectively 
separate the isobars associated with CAH analysis, the 400 bar pressure limit of the LC-20AD pumps is 
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not compatible with traditional UHPLC backpressures utilizing fully-porous stationary phase support 
materials.44 
 HPLC columns with superficially porous stationary phase support materials were, therefore, 
investigated. Superficially porous stationary phase supports consist of an inner sphere of solid silica with 
a thin layer of porous silica deposited on the surface.45 Columns packed with superficially porous 
stationary phase support can allow for the use of smaller particle sizes and higher mobile phase flow 
rates than would typically be possible at backpressures within acceptable limits of HPLC equipment. It 
was predicted that some of the benefits of UHPLC analysis could be attained without the need to 
purchase UHPLC equipment. 
 HPLC columns from the Kinetex™ line from Phenomenex (Torrance, CA, USA) utilize superficially 
porous stationary phase support material and were incorporated into this study. Two stationary phase 
ligands were analyzed to assess viability as a column option for 2nd tier CAH analysis. The Kinetex™ C18 
column was selected as a comparison to columns previously reported in the literature for 2nd tier CAH 
analysis.28,30–32,44 The Kinetex™ Biphenyl column was selected to determine if the biphenyl stationary 
phase ligand offered a more effective separation of isobaric compounds.43,46 The column dimensions 
selected for analysis were 2.6 µm particle size, 50 mm length, and 3.0 mm column internal diameter. 
2.3.1. C18 stationary phase ligand 
 
 A Kinetex™ C18, 2.6 µm, 50 x 3.0 mm HPLC column provided by Phenomenex (Torrance, CA, 
USA) was installed in-line between the autosampler injection valve and the electrospray ionization 
source. The column was kept at room temperature and subjected to a mobile phase gradient at a flow 
rate of 500 µL/min. Mobile phase constituent A consisted of water with 0.1% formic acid. Mobile phase 
constituent B consisted of methanol with 0.1% formic acid. A mixed analytical standard, consisting of all 
target analytes, internal standards, and isobaric interferences, each at a concentration of 16.7 ng/mL in 
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50:50 methanol: water with 0.1% formic acid was used for chromatography optimization studies. Of 
greatest concern was the resolution of isobaric compounds from one another and the overall 
chromatographic run time. The resolutions of the three isobars, 21-DOC, 11-DOC, and corticosterone 
(precursor m/z = 347.1) and isobars 17-OHP and deoxycorticosterone (precursor m/z = 331.3) were 
calculated using Equation 1: 
Equation 1. Chromatographic resolution equation 
𝑅# = 1.18	 ×	*
𝑡,- 	−	𝑡,/
𝑤1.23/ 	+	𝑤1.23-
5 
Rs is peak resolution, tR1 is the retention time for peak 1, tR2 is the retention time for peak 2, w0.5h1 is the 
full width at half maximum (FWHM) for peak 1, and w0.5h2 is the FWHM for peak 2.   
An initial exploratory gradient, depicted in Table 7, was used to evaluate the resolution 
capability of the column. Under these gradient conditions, the column showed adequate resolution of 
17-OHP and deoxycorticosterone, Rs = 2.75. However, 21-DOC was not fully resolved from its isobars, Rs 
= 1.11, and there was coelution between 11-DOC and corticosterone, shown in Figure 6. 
Table 7. Initial exploratory gradient for C18 column 
Time (min) %A %B 
0.01 40 60 
1.00 30 70 
3.50 25 75 
4.00 5 95 
4.50 5 95 
4.60 40 60 
5.00 40 60 
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Figure 6. Representative chromatographic profile of C18 column using initial exploratory gradient described in Table 7 depicted 
by the total ion chromatogram for all MRM transitions. 
  
 The mobile phase gradient was then extended, indicated in Table 8, incorporating a smaller 
slope of increase in mobile phase B over time in an attempt to allow for longer retention of isobars for 
increased resolution. While resolution of 17-OHP and deoxycorticosterone was improved at Rs = 4.62, 
the longer gradient failed to adequately separate 11-DOC from corticosterone. 21-DOC was fully 
resolved from 11-DOC and corticosterone using the long gradient, Rs = 2.11. Figure 7 shows a 
representative chromatogram of C18 separations using the long gradient depicted by the total ion 
chromatogram for all MRM transitions. 
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Table 8. Long gradient for C18 separations 
Time (min) %A %B 
0.01 40 60 
1.00 40 60 
8.50 25 75 
9.00 5 95 
9.50 5 95 
9.60 40 60 
10.50 40 60 
 
 
Figure 7. Representative chromatographic profile of C18 separations using long gradient described in Table 8 depicted by the 
total ion chromatogram for all MRM transitions.  
 
 As indicated by the initial exploratory and long gradients, the analytes of interest were eluting 
from the C18 column quite early in the gradient profile, before reaching high organic concentrations. 
Therefore, a series of gradients were explored that employed a long isocratic hold at the beginning of 
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the gradient profile. Baseline resolution of 21-DOC, corticosterone, and 11-DOC was achieved with a 5 
min isocratic hold at 50% B followed by ramp up to 95%, as indicated in Table 9. Figure 8 is a 
representative chromatogram of analyte separations using the long initial isocratic hold depicted by the 
total ion chromatogram for all MRM transitions. Though baseline resolution was achieved between 21-
DOC and corticosterone, Rs = 2.53, and between corticosterone and 11-DOC, Rs = 2.24, the drawbacks to 
this gradient profile were band broadening and lower sensitivity for the compounds that elute within 
the isocratic hold region. Additionally, the long run time of over 10 min was not conducive to high-
throughput analysis. 
Table 9. Gradient with long initial isocratic hold for C18 separations 
Time (min) %A %B 
0.01 50 50 
5.00 50 50 
8.50 25 75 
9.00 5 95 
9.50 5 95 
9.60 50 50 
10.50 50 50 
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Figure 8. Representative chromatographic profile of C18 separations using gradient with long initial isocratic hold at 50% B 
described in Table 9 depicted by the total ion chromatogram for all MRM transitions. 
 
 Finally, adjustments were made to the gradient profile to incorporate an isocratic hold at the 
beginning of the run but shorten the overall run time closer to 5 min per run. Unfortunately, none of the 
attempted gradient modifications were able to achieve a shorter run time while maintaining baseline 
resolution of isobars. 
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2.3.2. Biphenyl stationary phase ligand 
 
A Kinetex™ Biphenyl, 2.6 µm, 50 x 3.0 mm HPLC column provided by Phenomenex (Torrance, 
CA, USA) was installed in-line between the autosampler injection valve and the electrospray ionization 
source. The column was kept at room temperature and subjected to a mobile phase gradient at a flow 
rate of 500 µL/min. Mobile phase constituent A consisted of water with 0.1% formic acid. Mobile phase 
constituent B consisted of methanol with 0.1% formic acid. A mixed analytical standard, consisting of all 
target analytes, internal standards, and isobaric interferences, each at a concentration of 16.7 ng/mL in 
50:50 methanol: water with 0.1% formic acid was used for chromatography optimization studies.  
 A long gradient, summarized in Table 10, was employed initially in order to establish retention 
characteristics of the biphenyl stationary phase ligand. As indicated in Figure 9, all compounds were well 
retained on the column and baseline resolution was achieved for all isobars. 11-DOC and corticosterone 
were identified as the critical pair of closest eluting isobars. Baseline resolution, Rs = 2.08, of the critical 
pair was achieved under these conditions. 4-AD and deoxycorticosterone coelute on the biphenyl 
column, however these compounds are easily differentiated by the mass spectrometer due to differing 
precursor ions. 
 
 
Table 10. Long gradient for biphenyl separations 
Time (min) %A %B 
0.01 80 20 
8.00 5 95 
8.50 5 95 
8.51 80 20 
10.00 80 20 
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Figure 9. Representative chromatographic profile of biphenyl separations using long gradient described in Table 10 depicted by 
the total ion chromatogram for all MRM transitions. 
 
 The gradient was then modified to shorten the overall run time while attempting to maintain 
baseline resolution of the critical pair. As indicated in Table 11, the shortened gradient began with 50% 
mobile phase B and ramped to 95% B over 4.5 min. The overall runtime was reduced to 6 min and 
adequate resolution was maintained. Figure 10 shows a representative chromatogram of biphenyl 
separations using the shortened gradient depicted by the total ion chromatogram for all MRM 
transitions. Baseline resolution of the critical pair was maintained, Rs = 2.21, under these modified 
gradient conditions. 
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Table 11. Shortened gradient for biphenyl separations 
Time (min) %A %B 
0.01 50 50 
4.50 5 95 
5.00 5 95 
5.01 50 50 
6.00 50 50 
 
 
Figure 10. Representative chromatographic profile of biphenyl separations using shortened gradient described in Table 11 
depicted by the total ion chromatogram for all MRM transitions. 
  
The biphenyl stationary phase ligand achieved better resolution of isobaric compounds within a 
shorter run time compared to the C18 stationary phase ligand. The biphenyl column was therefore 
selected for further optimization and validation. 
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2.3.3. Column temperature optimization 
 
 After selection of biphenyl as the optimal stationary phase ligand, HPLC column temperature 
optimization was performed. By using a column heater, a more consistent column temperature is 
maintained as compared to ambient room conditions and higher column temperatures can allow for 
faster separations at lower backpressure. Replicate injections (N = 5) of a mixed analytical standard, 
consisting of all target analytes, internal standards, and isobaric interferences, each at a concentration 
of 16.7 ng/mL in 50:50 methanol: water with 0.1% formic acid were performed under the same mobile 
phase gradient conditions, varying only the temperature of the HPLC column heater. Experiments were 
performed at room temperature (21), 30, 40, 50, and 60 °C. Results for retention time, peak width, and 
resolution of the critical isobaric pair were compared at all temperatures.  
 All data metrics were acceptable at each of the comparative column temperatures. A column 
temperature of 50 °C was selected due to faster elution as compared to room temperature which 
maintaining baseline separation of the critical pair. Additionally, a column temperature of 60 °C was 
avoided due to this being the maximum allowable column temperature to avoid significant column 
degradation as indicated by the manufacturer. Using the optimized column temperature of 50 °C, the 
biphenyl gradient conditions were further modified to the final conditions presented in Table 12, with a 
4.5 min run time. The increased retention of the target compounds on the biphenyl stationary phase 
ligand as compared to the C18 stationary phase ligand also allowed for the mobile phase gradient profile 
to be further modified to begin with a higher (65%) organic concentration in the mobile phase, which 
allowed for a shorted overall gradient profile as well as faster equilibration back to initial conditions 
following elution of the last compounds from the column. Figure 11 shows a representative 
chromatogram of biphenyl separations using the shortened gradient depicted by the total ion 
chromatogram for all MRM transitions. 
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Table 12. Fully optimized mobile phase gradient conditions. 
Time (min) A% B% Flow Rate (µL/min) 
0.00 35 65 500 
3.00 5 95 500 
3.50 5 95 500 
3.51 35 65 500 
4.50 35 65 500 
 
 
Figure 11. Representative chromatographic profile of biphenyl separations using fully optimized gradient conditions and heated 
column as described in Table 12, depicted by the total ion chromatogram for all MRM transitions. 
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2.4 DBS extraction optimization 
 
2.4.1. DBS Extraction Solution formulation 
 
 Based upon extraction solution formulations reported in the literature,28,30,32,41 initial DBS 
extraction experiments were performed using a formulation consisting of 80:20 acetonitrile: water and a 
non-aqueous formulation consisting of 50:50 acetonitrile: methanol. Each formulation was enriched to 2 
ng/mL of each stable isotope-labeled internal standard. DBS Quality Control (QC) materials provided by 
the Newborn Screening Quality Assurance Program at the Centers for Disease Control and Prevention 
(CDC NSQAP) were extracted and analyzed by the optimized LC-MS/MS method. The formulation of 
80:20 acetonitrile: water showed better signal during comparative analysis and was selected for further 
optimization (data not shown). 
 Formulations of DBS Extraction Solution containing 70:30 acetonitrile: water, 80:20 acetonitrile: 
water, and 90:10 acetonitrile: water were prepared, each enriched to 2 ng/mL of each stable isotope-
labeled internal standard. DBS QC materials from CDC NSQAP were extracted and analyzed using the 
optimized LC-MS/MS method. 80:20 acetonitrile: water with 2 ng/mL of each internal standard was 
selected as the final DBS Extraction Solution formulation. 
2.4.2. DBS extraction procedure optimization 
 
 The DBS extraction procedure was optimized using DBS QC materials from CDC NSQAP. DBS 
extraction steps mostly follow those previously reported in the literature.30,32,41 DBS eluate transfer 
volume and final reconstitution volume began at 150 µL and 80 µL, respectively but were optimized to 
175 µL and 50 µL, respectively in order to maximize assay signal-to-noise at low analyte concentrations. 
The plate drying time was optimized to 20 min to reach complete dryness. It was determined that the 
final reconstituted volume needed to be transferred to a low-volume 96-well plate in order to enable a 
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higher liquid column height in each well to ensure the autosampler needle can reproducibly draw the 
full 20 µL injection volume from each extract well. Plate centrifugation was utilized to help remove 
residual particulate matter from extraction of DBS punches as well as to remove air bubbles from the 
low-volume 96-well plate prior to loading extracts on the instrument. 
2.4.3. Optimization of number of DBS punches per well 
 
 2nd tier CAH methods reported in the literature often report the use of large DBS punches, 4.8 
mm or 6.0 mm in diameter, in order to ensure an adequate volume of blood within the extract to reach 
assay sensitivity requirements.28,30–32 Large DBS punches, however, can create logistical problems within 
the NBS laboratory. The ability to punch large DBS punches may be limited by the area available within a 
dried blood spot. This can be particularly problematic for 2nd tier analyses as DBS have often already 
received several punches for 1st tier analysis prior to 2nd tier testing being initiated. Similarly, removing a 
large DBS punch from a specimen limits the area of dried blood available for subsequent analysis. 
Additionally, many NBS assays utilize 3.2 mm (1/8 in) punches, yielding approximately 3.1 µL blood per 
punch. Because this is the most common punch size, most automated or semi-automated punching 
equipment is preconfigured with 3.2 mm punch heads. Moving to a larger punch size may require 
installation of a different punch head. For these reasons, the NBS laboratory opted to utilize a 3.2 mm 
punch size for 2nd tier CAH analysis.  
 Initial method optimization work was performed using two 3.2 mm DBS punches per well, 
yielding approximately 6.2 µL blood per well. Low concentration DBS materials enriched by the NBS 
laboratory were subsequently used to determine if additional punches were needed to achieve 
acceptable signal-to-noise at the lower limit of quantitation for the assay. By a comparative study, it was 
determined that three 3.2 mm punches per well, yielding approximately 9.3 µL blood per well, were 
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necessary to reliably achieve acceptable signal-to-noise at low analyte concentrations. Subsequently, 
the assay was validated using three 3.2 mm DBS punches per well. 
 
2.5 Summary of method development 
 
 The method development process yielded comprehensive method parameters that achieved the 
main goals for the assay. The core-shell biphenyl column allowed for baseline resolution of isobars 
utilizing a rapid gradient profile at system backpressures amenable to HPLC equipment. The only major 
modification to the existing HPLC-MS/MS instrumentation was addition of a column heater. Following 
optimization of the method parameters, the assay needed to be validated prior to full implementation 
for analysis of patient DBS specimens. 
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CHAPTER 3: EXPERIMENTAL 
 
 
 
3.1 Chemicals and reagents 
 
 Cortisol, 17-OHP, 4-AD, 21-DOC, 11-DOC, corticosterone, and 11-deoxycorticosterone 
(deoxycorticosterone) analytical standards as well as cortisol-D4, 17-OHP-D8, 4-AD-13C3, 21-DOC-D8, and 
11-DOC-D5 isotope-labeled internal standards were purchased from Cerilliant Corporation (Round Rock, 
TX, USA). Optima LC-MS grade water, Optima LC-MS grade methanol, and Optima LC-MS grade 
acetonitrile were purchased from Fisher Scientific (Pittsburg, PA, USA).  Formic acid was purchased from 
Acros Organics (Fairlawn, NJ, USA). Washed packed human red blood cells and whole blood were 
purchased from ZenBio (Research Triangle Park, NC, USA). Double charcoal-stripped defibrinated human 
plasma was purchased from SeraCare (Milford, MA, USA). Unbuffered sterile saline was purchased from 
Moltox Molecular Technology, Inc. (Boone, NC, USA). 
 
3.2 Materials and equipment 
 
 Pools of hematocrit-adjusted steroid-depleted human blood used for dried blood spot calibrator 
and quality control specimen production were prepared by washing red blood cells and combining with 
double charcoal-stripped defibrinated human plasma. Units of washed packed human red blood cells or 
human whole blood were aliquoted to 50 mL polypropylene conical tubes purchased from Becton 
Dickinson (Franklin Lakes, NJ, USA). An equal volume of sterile saline was added to each tube and mixed 
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using an open-air rocker purchased from Fisher Scientific (Pittsburg, PA, USA). The tubes were then 
centrifuged using an Allegra X-14R centrifuge by Beckman Coulter, Inc. (Brea, CA, USA). The plasma or 
saline fraction was removed from each tube using an EV320 Evac Waste System by Argos Technologies, 
Inc. (Vernon Hills, IL, USA). Blood units were washed and least three times. Hematocrit levels were 
evaluated using a HemataStat II hematocrit centrifuge from EKF Diagnostics (Stanbio Laboratory, 
Boerne, TX, USA).  
 A Wallac DBS Puncher from PerkinElmer (Waltham, MA, USA) was used to punch 3.2 mm discs 
from dried blood spots into 96-well round bottom polypropylene plates. All pipetting steps were carried 
out using single and multichannel Finnpipette F2 adjustable-volume pipettes with Finntip polypropylene 
tips from ThermoFisher Scientific (Waltham, MA, USA). Centrifugation of 96-well plates was carried out 
using an ST-16 centrifuge with M-20 microplate rotor from ThermoFisher Scientific (Waltham, MA, USA). 
A digital microplate shaker from ThermoFisher Scientific (Waltham, MA, USA) was utilized to agitate 
microplates during sample extraction. An Evaporex EVX192 plate dryer from Apricot Designs (Covina, 
CA, USA) was utilized for plate drying steps. Round-bottom polypropylene 96-well plates from Corning 
(Salt Lake City, UT, USA), V-bottom polypropylene NUNC 96-well plates from Thermo Scientific 
(Rochester, NY, USA), and low-volume V-bottom polypropylene 96-well plates from Abgene 
(Portsmouth, NH, USA) were utilized for sample preparation and analysis. 
 
3.3 Stock solution and working solution preparation 
 
 Analytical standards in 1 mL aliquots each of cortisol, 17-OHP, 11-DOC, and corticosterone were 
purchased from Cerilliant Corporation (Round Rock, TX, USA) as stock solutions at 1 mg/mL in methanol. 
Analytical standards in 1 mL aliquots each of 21-DOC and deoxycorticosterone were purchased from 
Cerilliant as stock solutions at 100 µg/mL methanol. Analytical standards in 1 mL aliquots of 4-AD were 
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purchased from Cerilliant as stock solution at 1 mg/mL in acetonitrile. Analytical standards in 1 mL 
aliquots each of cortisol-D4, 17-OHP-D8, 21-DOC-D8, and 11-DOC-D5 stable isotope-labeled internal 
standards were purchased from Cerilliant as stock solutions at 100 µg/mL in methanol. Analytical 
standards in 1 mL aliquots of 4-AD-13C3 stable isotope-labeled internal standard were purchased from 
Cerilliant as stock solution at 100 µg/mL in acetonitrile.  
 Each of the 1 mg/mL analyte stock solutions was diluted to 1 µg/mL in methanol to prepare 
individual intermediate stocks. Individual intermediate stocks of all un-labeled compounds were also 
prepared at 5 µg/mL in methanol. 
 For mass spectrometry infusion experiments, individual stocks of all analytes were prepared at 
200 ng/mL in 50:50 methanol: water with 0.1% formic acid. Stable isotope-labeled 100 µg/mL internal 
standard stocks were combined in equal volumes, mixed, and then were divided into 50 µL aliquots at a 
concentration of 20 µg/mL each. Aliquots were sealed in individual screw-cap vials and stored in freezer 
(-20 + 5°C) until use. DBS Extraction Solution was prepared by adding the full contents of one mixed 
internal standard vial to 500 mL of 80:20 acetonitrile: water, to yield a final internal standard 
concentration of 2 ng/mL. Reconstitution Solution was prepared at 50:50 methanol: water with 0.1% 
formic acid. 
 For preparation of dried blood spot calibration and quality control materials, a mixed analyte 
stock containing cortisol, 17-OHP, 4-AD, 21-DOC, and 11-DOC was prepared in methanol at a 
concentration of 25 µg/mL of each analyte. This mixed analyte stock was further diluted to prepare 
intermediate stocks at 4 µg/mL and 0.25 µg/mL, both in methanol. 
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3.4 Preparation of hematocrit-adjusted dried blood spot calibration standards, quality control 
standards, and validation study standards 
 
 Dried blood spots (DBS) were prepared for use as calibration standards, quality control 
standards, and materials specific to the linearity, limit of quantitation, and interference studies for 
method validation. The prepared DBS were manufactured by enriching hematocrit-adjusted human 
blood pools with standard concentrations of target analytes, spotting the blood on filter paper cards and 
allowing them to dry before storing in a freezer (-20 + 5 °C) with desiccant. 
 Hematocrit-adjusted human blood pools, depleted of target steroids and precursors, were 
prepared by repeated washing of purchased units of human red blood cells or human whole blood to 
yield washed packed red blood cells. Red blood cells or whole blood were thoroughly mixed with equal 
volumes of unbuffered sterile saline and centrifuged at 3000 rpm, under refrigeration at approximately 
4 °C. Vacuum aspiration then was used to remove as much of the plasma, saline, and buffy coat fractions 
as possible. The washing, centrifugation, and vacuum aspiration process was repeated three times for 
each blood unit. The washed packed red blood cells then were mixed with defibrinated, charcoal-
stripped human plasma, mimicking human serum, to reach a desired hematocrit level of 50 + 1%. 
Hematocrit levels were verified using a hematocrit centrifuge. Additional volumes of washed packed red 
blood cells or defibrinated, charcoal-stripped plasma were added to each blood pool to adjust the 
hematocrit level up or down, respectively. Once the desired hematocrit level was reached, the blood 
pools were ready for enrichment with target compounds. 
 Class A volumetric glassware was used to prepare 25 mL volumes of calibrator and quality 
control standards. To prepare calibration standards at concentrations of 1, 2, and 5 ng/mL serum, a 
predetermined volume of 0.25 µg/mL mixed analyte stock was added to each volumetric flask. An 
additional predetermined volume of methanol was added to each volumetric flask in order to keep the 
solvent volume in each flask identical. Each flask was then filled to volume with hematocrit-adjusted 
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steroid-depleted blood, capped, and thoroughly mixed by inversion. Similarly, to produce calibration 
standards at concentrations of 20, 100, and 500 ng/mL serum, a predetermined volume of 25 µg/mL 
mixed analyte stock was added to each volumetric flask followed by a predetermined volume of 
methanol. Each flask was then filled to volume with hematocrit-adjusted steroid-depleted blood, 
capped, and thoroughly mixed by inversion. Low, medium, and high concentration quality control 
standards were prepared by adding a predetermined volume of 4 µg/mL mixed analyte stock to each 
volumetric flask followed by a predetermined volume of methanol. Each flask was then filled to volume 
with hematocrit-adjusted steroid-depleted blood, capped, and thoroughly mixed by inversion. 
Additionally, a flask containing only an equivalent volume of methanol as the calibrator and quality 
control standards was filled to volume with hematocrit-adjusted steroid-depleted blood, capped, and 
thoroughly mixed by inversion to serve as a matrix blank. All calibrator and quality control materials 
were filtered through glass wool prior to spotting on filter paper. 
 In addition to calibrator and quality control standards, enriched blood materials specific to 
method validation activities were prepared in 2 mL volumes prior to being spotted on filter paper. Low 
concentration enriched blood standards were prepared at concentrations of 0.25 and 0.50 ng/mL serum 
using the 0.25 µg/mL mixed analyte stock and equivalent volumes of additional methanol. These 
materials were used to evaluate the lower limit of quantitation (LOQ) for the assay. A high concentration 
enriched blood standard was prepared at 1000 ng/mL serum using the 25 µg/mL mixed analyte stock 
and equivalent volume of methanol. The 1000 ng/mL serum standard was used for linearity and 
carryover experiments. For interference studies, 2 mL volumes of hematocrit-adjusted steroid-depleted 
blood were enriched with varying concentrations of target analytes as well as known isobaric 
interferences. The concentration scheme for the interference study materials is provided in Table 13. 
The critical pair of isobars, 11-DOC and corticosterone, were enriched at opposing concentrations to 
determine whether varying concentrations of the non-target analyte corticosterone showed any 
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unfavorable influence on linear response or calculated concentrations of the target analyte 11-DOC. 
Additionally, by enriching high concentrations of corticosterone with low concentrations of 11-DOC the 
ability of the instrument software peak identification and integration algorithm to correctly assign the 
11-DOC peak was evaluated. Deoxycorticosterone and 4-AD were enriched at opposing concentrations 
because these compounds co-elute from the HPLC column under the optimized chromatographic 
conditions for the assay. The influence of varying concentrations of the non-target compound 
deoxycorticosterone on the linear response or calculated concentration of the target compound 4-AD 
was evaluated. 
Table 13. DBS enrichment concentrations for interference study. All concentrations are ng/mL serum. 
Sample  [CORT] [21-DOC] [11-DOC] [Corticosterone] [17-OHP] [4-AD] [Deoxycorticosterone] 
A 250 25 0 500 50 10 100 
B 500 10 5 250 100 25 50 
C 0 5 10 100 250 50 25 
D 5 0 25 50 500 100 10 
E 10 500 50 25 0 250 5 
F 25 250 100 10 5 500 0 
G 50 100 250 5 10 0 500 
H 100 50 500 0 25 5 250 
 
 All enriched blood solutions were filtered through glass wool (where volumes allowed) and then 
spotted on Whatman® 903 filter paper using a digital repeater pipette set to a dispense volume of 75 µL 
per blood spot. Spotted filter paper cards were allowed to dry at room conditions before being stored in 
a freezer with desiccant until analysis. In all, over 3000 dried blood spots were produced for method 
validation experiments. 
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3.5 HPLC parameters 
 
 HPLC equipment used for method development and validation experiments included: Shimadzu 
pumps LC-20AD, system controller CBM-20A, solvent degasser DGU-20A3 (Shimadzu, Kyoto, Japan). An 
HTC PAL autosampler from CTC Analytics (Zwingen, Switzerland) was used to introduce samples into the 
mobile phase flow. An EchoTherm CO20 column heater from Torrey Pines Scientific (Carlsbad, CA, USA) 
was used. A Kinetex Biphenyl column (3.0 x 50 mm, 2.6 µm) with Biphenyl SecurityGuard ULTRA guard 
cartridges from Phenomenex (Torrance, CA, USA) was used for reversed phase liquid chromatography. A 
binary gradient using two LC-20AD pumps was carried out with mobile phase A consisting of water with 
0.1% formic acid and mobile phase B consisting of methanol with 0.1% formic acid. Gradient conditions 
are summarized in Table 12 in section 2.3.3 (page 35), and a typical chromatogram is shown in Figure 11 
in section 2.3.3 (page 35). The mobile phase flow rate for routine separations was 500 µL/min. The 
column temperature was maintained at 50 °C and sample plates were maintained in the autosampler at 
room conditions. Autosampler syringe and injection valve wash cycles between injections consisted of 
four cycles of 100 µL 50:50 methanol: water with 0.1% formic acid. The autosampler injection volume 
was set to 20 µL. 
The HPLC column was slowly equilibrated each day using a modified version of the routine 
method. The column equilibration method utilized the same initial gradient conditions, however the 
flow rate began at 50 µL/min and was slowly increased to 500 µL/min over a period of 10 minutes. 
 
3.6 Mass spectrometer parameters 
 
 Tandem mass spectrometry was carried out using a Sciex API 4000 (Framingham, MA, USA) 
triple quadrupole mass spectrometer operated in positive electrospray ionization mode with multiple 
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reaction monitoring (MRM) of target analytes and stable isotope-labeled internal standards. 
Optimization of ionization and MRM parameters was performed by direct infusion of 200 ng/mL stock 
solutions using a syringe pump at a flow rate of 10 µL/min as described in Chapter 2. Common mass 
spectrometer parameters, optimized for maximum sensitivity and shared by all target analytes and 
internal standards, include: ion spray voltage 4000 V, desolvation temperature 550 °C, collision assisted 
dissociation (CAD) gas pressure 6.00 arbitrary units, nebulizer gas (GS1) flow 45 arbitrary units, heater 
gas (GS2) flow 40 arbitrary units, curtain gas flow 45 arbitrary units, entrance potential (EP) 10 V.  Table 
14 shows optimized, compound-specific MRM parameters. 
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Table 14. Multiple Reaction Monitoring (MRM) parameters. 
Analyte Q1 Precursor Ion (m/z) 
Q3 Product 
Ion (m/z) 
Dwell Time 
(msec) DP (V) CE (V) CXP (V) 
4-AD_Q 287.10 109.00 25 86 35 8 
4-AD_C 287.10 97.10 50 86 51 6 
4-AD_IS 290.20 112.00 15 91 35 8 
17-OHP_Q 331.30 109.00 50 96 39 8 
17-OHP_C 331.30 97.10 50 96 61 6 
17-OHP_IS 339.20 100.00 15 101 43 8 
11-DOC_Q 347.10 109.00 25 96 41 8 
11-DOC_C 347.10 97.00 25 96 43 6 
11-DOC_IS 352.10 112.80 15 96 47 8 
21-DOC_Q 347.10 311.10 50 96 25 16 
21-DOC_C 347.10 175.10 50 96 29 12 
21-DOC_IS 355.20 319.00 15 101 23 20 
CORT_Q 363.10 120.90 50 96 35 8 
CORT_C 363.10 326.90 50 96 23 20 
CORT_IS 367.10 121.00 15 60 52 12 
DP, declustering potential; CE, collision energy; CXP, collision cell exit potential; _Q, quantitation ion 
transition; _C, confirmation ion transition, _IS, stable isotope-labeled internal standard ion transition 
 
3.7 Sample preparation parameters 
 
 Dried blood spots from patient specimens, calibrators, and quality control materials were 
analyzed in duplicate on each 96-well plate and were prepared for LC-MS/MS analysis using the same 
protocol. Three 3.2 mm discs were punched from the dried blood spot into a single well of a round-
bottom 96-well plate. DBS Extraction Solution, 200 µL, was added to each well containing DBS punches. 
The plate was covered with aluminum foil and placed on a plate shaker at 300 rpm for 30 minutes. 
Following the shaking period, plates were centrifuged at 1500 x g for 10 minutes. Following 
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centrifugation, 175 µL of supernatant was transferred to a V-bottom NUNC 96-well plate. The DBS 
punches were discarded. The NUNC 96-well plate containing supernatant was placed on a plate dryer 
and was concentrated to dryness under heated air. The dried wells were reconstituted to 50 µL using 
Reconstitution Solution. The plate was covered with foil and placed on a plate shaker at 300 rpm for 5 
minutes. The entire reconstituted volume was then transferred to a low-volume V-bottom plate. The 
low-volume 96-well plate was covered with foil and centrifuged at 1500 x g for 2 minutes to remove any 
bubbles. Following centrifugation, the plate was transferred to the autosampler for LC-MS/MS analysis. 
 
3.8 Method validation experiments 
 
 Following HPLC, tandem mass spectrometry, and sample preparation parameter optimizations, 
the full method was evaluated using several criteria to determine expected performance and reliability 
prior to full implementation within the Newborn Screening Laboratory. The Newborn Screening 
Laboratory is part of Virginia’s Public Health Laboratory and is accredited and audited under the Clinical 
Laboratory Improvement Amendments (CLIA). Method validation experiments were performed to meet 
the criteria under CLIA for evaluation of a laboratory-developed test. 
3.8.1. Matrix effects 
 To study matrix effects, a tee union was installed in between the outlet end of the HPLC column 
and the inlet for the electrospray ionization source. An infusion line was connected to the third port of the 
tee union. A syringe containing a 200 ng/mL infusion solution of all target analytes and stable isotope-
labeled internal standard compounds was connected to the infusion line. Using a syringe pump set to a 
flow rate of 5 µL/minute, the infusion solution was pumped into the HPLC column eluent and mixed before 
being introduced to the electrospray ionization source. 
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 Matrix contributions to ionization suppression or enhancement were measured by studying the 
multiple reaction monitoring (MRM) signal for each of the target analytes and internal standards at the 
mass spectrometer. Through constant flow of the infusion solution, a flat, steady MRM signal is anticipated 
for each analyte trace if no matrix effects are present. As matrix components are introduced to the system 
and eluted through the HPLC column, dips in MRM signal indicate ionization suppression due to matrix 
effects while increases in MRM signal indicate ionization enhancement.  
 This experiment was conducted while introducing only solvent into the system (no matrix), 
introducing extracts of filter paper (no blood matrix), and introducing extracted dried blood spot matrix in 
order to compare ionization effects based upon the various components. 
3.8.2. Carryover 
 Carryover effects were studied by analyzing replicates (N = 3) of DBS extracts containing high 
(1000 ng/mL serum) concentrations of target compounds followed immediately by analysis of DBS extracts 
of unenriched (blank) blood matrix. The DBS blank analyses were scrutinized to determine how much 
quantifiable signal of each target compound was detectable in the DBS blanks. The experiments were 
repeated for two assays. 
 Additionally, to test whether carryover was occurring due to over-retention or poor elution of 
target compounds from the HPLC column, replicates of high concentration (1000 ng/mL serum) DBS 
extracts were analyzed. Immediately following the final high concentration replicate, the mobile phase 
gradient program was repeated without injection of any new extracted material from the autosampler (no 
syringe). The run was scrutinized to determine if any quantifiable signal was present for any of the target 
compounds based upon elution of over-retained materials from the HPLC column. 
3.8.3. Interfering or co-eluting substances 
DBS materials were enriched with pre-determined concentrations of potentially interfering 
isobaric compounds. One set of isobaric compounds that were studied included 21-deoxycortisol (21-
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DOC), 11-deoxycortisol (11-DOC), and corticosterone, all sharing the sample precursor ion mass-to-
charge ratio of 347.10 m/z. 21-DOC and 11-DOC are target analytes for the assay whereas 
corticosterone is a possible interferent. A second set of isobaric compounds that were studied included 
17-OHP and deoxycorticosterone, both sharing the same precursor mass-to-charge ratio of 331.30 m/z. 
17-OHP is a target analyte of the assay and deoxycorticosterone is a possible interferent. 
Deoxycorticosterone also co-elutes with androstenedione (4-AD), a target compound for the assay. 
Replicates of the enriched DBS materials were analyzed to study whether linear response of the 
target compounds was maintained in the presence of varying concentrations of isobaric or co-eluting 
interferents. Additionally, the peak resolution was calculated between the closest eluting pair of isobaric 
compounds, 11-DOC and corticosterone, considered the critical pair for HPLC separation, to ensure that 
baseline resolution (> 1.5) was achieved in order to avoid potential influence on concentration 
calculations.  
3.8.4. Linearity and lower limit of quantitation (LOQ) 
Linearity was assessed by plotting replicate (N=12) internal calibration responses of DBS 
materials enriched with analyte concentrations ranging from 0.25 ng/mL serum up to 1000 ng/mL 
serum. The plot of the replicates was compared to linear and polynomial fit models to determine across 
what concentration range the assay showed adequate linearity for each analyte. Linearity was 
considered acceptable when the mean of the replicate responses did not deviate more than 15% from 
the linear fit model at each concentration level. 
Lower limit of quantitation (LOQ) was assessed by replicate analyses (N=12) of DBS materials 
with decreasing concentrations of each target compound. Two metrics were utilized to determine the 
LOQ: signal-to-noise ratio and replicate reproducibility (%CV). The LOQ for each target compound was 
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determined as the concentration at which analyte response exceeds a 10:1 signal-to-noise ratio and 
replicate reproducibility of less than 20% CV. 
3.8.5. HPLC column batch-to-batch reproducibility 
In order to evaluate anticipated reproducibility of HPLC columns as they were replaced over 
time, columns from different production lots were compared. A total of six Phenomenex Kinetex 
Biphenyl, 2.6 µm, 50 x 3.00 mm HPLC columns were used for the comparison study. The columns were 
from three different production lots, two columns from each lot.  
Replicate injections of unextracted standard solution (N=5 injections per column) containing 
target analytes, stable isotope-labeled internal standard compounds, and potential isobaric 
interferences were analyzed for column comparison. Metrics for peak area, retention time, peak width, 
and resolution of critical pair (11-DOC from corticosterone) were compared across column lots. 
Multiple extracts of DBS QC (low, medium, high) were pooled and repeatedly analyzed (N = 5 
replicates per QC level per column) on all six columns to compare calculated concentrations, peak areas, 
peak widths, and analyte retention times. 
3.8.6. Recovery 
Analyte recoveries were calculated using replicated analyses (N=10) of DBS QC material 
provided by the CDC NSQAP.33 Internal calibration was performed to determine calculated analyte 
concentrations using Equation 2: 
Equation 2. Internal calibration equation 
𝐶7879:;<	 =
=𝐼7879:;< 	× 	𝑉<@; 	×	𝐶ABC
(𝐼AB	 × 	𝑉EB)
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Canalyte is analyte concentration, Ianalyte is analyte response intensity, Vext is the extract volume, CIS is the 
internal standard concentration, IIS is the internal standard response intensity, and VBS is the volume of 
serum in the DBS extract. By utilizing internal calibration, raw recoveries for each analyte were able to 
be obtained. 
3.8.7. Accuracy and precision 
Method accuracy and precision were evaluated both inter- and intra-run using replicate analysis 
of DBS QC materials. Inter-run precision and accuracy data included 52 replicates each of three levels of 
QC (low, medium, high) utilizing three analysts with 26 analytical runs over a period of 15 days. Each 
analytical run contained two replicates of each QC and no more than two analytical runs were 
completed per day. Intra-run precision and accuracy were evaluated utilizing 25 replicates of each DBS 
QC level (low, medium, high) within a single analytical run. 
 
3.8.8. Extract stability 
Extract stability was evaluated by preparing pools of DBS extracts, including blanks, calibrators, 
QC, and NSQAP materials. Pooled extracts then were divided among seven microtiter plates and 
covered with foil. One plate was analyzed on the day of extraction (Day 0). The remaining six plates were 
divided into two subgroups of three plates each. One subgroup was stored at room conditions while the 
other subgroup was stored under refrigeration (1-5°C). At one, two, and seven days post-extraction, one 
plate from each subgroup was analyzed to compare metrics such as calculated analyte concentrations 
and analyte peak area. 
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3.8.9. Ruggedness 
Multiple variable factors were introduced into the study wherever practical in order to ensure 
overall assay ruggedness. Three analysts performed extractions, instrument analysis and data review 
throughout the validation. Precision, accuracy, and clinical sensitivity/specificity analyses were 
performed over a period of 16 days, by three analysts, with no more than two assays with two QC 
replicates each being run on any given day. Multiple lots of the various solvents and HPLC columns were 
utilized throughout the validation study. Mobile phase and DBS Extraction Solution preparations were 
made by multiple analysts throughout the study. 
3.8.10. Clinical sensitivity and specificity 
Double-blinded de-identified NBS specimens were analyzed in duplicate using the proposed 
HPLC-MS/MS assay. Results of the patient sample analyses were evaluated using a provisional cutoff 
algorithm to establish an interpretation of either within normal limits, abnormal (requiring request of a 
repeat specimen), critical (requiring immediate referral to follow-up), or unsatisfactory (consistent 
results were not able to be obtained). The 1st tier 17-OHP results and clinical outcomes for each patient 
specimen were unknown to the three individuals participating in the validation study prior to analysis 
and interpretation using the provisional cutoff algorithm.  
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CHAPTER 4: RESULTS AND DISCUSSION 
 
 
 The optimized LC-MS/MS method needed to be validated prior to being moved into production 
within the laboratory and being used to report patient results. The method was validated as a 
laboratory-developed test for implementation and audit under the Clinical Laboratory Improvement 
Amendments (CLIA).47 Method performance and characteristics that were validated include matrix 
effects, carryover, potential interfering substances, linearity, lower limit of quantitation, HPLC column 
reproducibility, accuracy and precision, clinical sensitivity and specificity, recovery, extract stability, and 
ruggedness. 
 
4.1 Matrix effects 
 
 Matrix effects leading to ionization suppression or enhancement were studied by infusing a 
mixed standard of all target analytes and internal standard compounds into the HPLC column eluent 
prior to ionization at the electrospray ionization source and running the mobile phase gradient profile. 
Experiments were conducted while injecting only solvent onto the column (no matrix), injecting extracts 
of filter paper (no blood matrix), and injecting extracted, unenriched dried blood spot matrix in order to 
compare ionization effects based upon the various matrix components. Figure 12 shows overlaid 
representative total ion chromatograms of all MRM transitions of matrix effect experiments comparing 
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ionization suppression when solvent (black trace) or dried blood spot extract (blue trace) are injected 
on-column. A representative total ion chromatogram of all MRM transitions of the typical analyte 
elution profile is overlaid (red trace) to compare ionization suppression regions relative to analyte 
retention times. Analysis with only solvent showed the least ionization suppression while ionization 
suppression effects increased with the introduction of extracted filter paper and still further with the 
introduction of extracted blood matrix. In all cases, initial severe ionization suppression occurs as 
unretained compounds elute from the HPLC column and ionization signal recovers across the course of 
the gradient HPLC run. The use of stable isotope-labelled internal standard compounds for quantitation 
of all target compounds helps to mitigate ionization suppression effects as these compounds co-elute 
with their respective target analytes. 
 
Figure 12. Representative total ion chromatograms of all MRM transitions of matrix effect experiments comparing ionization 
suppression when injecting solvent (black trace) or dried blood spot extract (blue trace). The overlaid red trace shows typical 
analyte elution profile. 
 
4.2 Carryover 
 
 Experiments were conducted to determine full system carryover as well as carryover due only to 
overloading or over-retention of target analytes on the HPLC column. To test for full system carryover, 
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three replicates of DBS extracts containing concentrations of 1000 ng/mL serum of cortisol, 21-DOC, 11-
DOC, 17-OHP, and 4-AD were analyzed. Immediately following the final high concentration replicate, 
DBS extracts of unenriched blood matrix were analyzed. Figure 13 shows a total ion chromatogram of all 
MRM transitions of high concentration DBS extract analysis as well as a total ion chromatogram of all 
MRM transitions of unenriched DBS extract that immediately followed. Internal standard ion traces are 
removed from the unenriched DBS extract chromatogram as the internal standard peaks give the 
illusion of carryover. HPLC column overloading or over-retention was tested by analyzing three 
replicates containing concentrations of 1000 ng/mL serum of cortisol, 21-DOC, 11-DOC, 17-OHP, and 4-
AD followed immediately by repeating the mobile phase gradient profile with no injection from the 
autosampler. Figure 14 shows a total ion chromatogram of all MRM transitions of a high concentration 
DBS extract analysis as well as a total ion chromatogram of all MRM transitions from a repeat of the 
mobile phase gradient profile without injection from the autosampler. 
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Figure 13. Representative total ion chromatogram of all MRM transitions from repeated analysis of high concentration DBS 
extracts (top) and total ion chromatogram of all MRM transitions from analysis of unenriched DBS extract with internal 
standard traces removed (bottom). 
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Figure 14. Representative total ion chromatogram of all MRM transitions of repeated analysis of high concentration DBS 
extracts (top) and total ion chromatogram of all MRM transitions of repeat of mobile phase gradient profile with no injection 
from autosampler (bottom). 
 
Both carryover experiments showed acceptable results as no detectable carryover was 
observed. Calculated concentrations for analytes within the DBS blank extracts were below reportable 
limits and were in line with typical analysis of DBS blanks. No discernable peaks were detected to 
indicate over-retention on the HPLC column. The high concentration DBS extracts used in carryover 
experiments exceed the anticipated analyte concentrations within most patient specimens analyzed by 
this assay. 
 
4.3 Interfering or co-eluting substances 
 
 During repeated analysis of DBS extracts from materials enriched with varying concentrations of 
potential isobaric interferences, all isobaric compounds were adequately resolved under the optimized 
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HPLC gradient conditions using the biphenyl stationary phase ligand. The critical pair of 11-DOC and 
corticosterone showed baseline resolution in all experiments. The co-elution of deoxycorticosterone 
with 4-AD did not negatively impact the ability to properly quantify 4-AD using the assay, given the fact 
that 4-AD and deoxycorticosterone have different precursor-to-product ion transitions and are 
therefore able to be differentiated by the mass spectrometer. 
 An example of baseline resolution of the critical pair, 11-DOC and corticosterone, from a DBS 
extract containing low concentration (5 ng/mL serum) of the 11-DOC target analyte and high 
concentration (250 ng/mL serum) of the potential interference, corticosterone, is shown in Figure 15. By 
achieving baseline resolution, the instrument peak detection and integration software was able to 
correctly identify the target compound, regardless of the concentration difference between the target 
and the interference. 
 
 
Figure 15. Representative extracted ion chromatogram example of baseline resolution of critical pair from interference study. 
Even at much lower concentration within the sample, the 11-DOC peak was successfully identified and integrated by the 
quantitation software. The extracted ion trace depicted is the quantitation ion transition for 11-DOC (347.10 à 109.00 m/z). 
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4.4 Linearity and lower limit of quantitation (LOQ) 
 
 Using enriched dried blood spot calibration materials, internal calibration responses were 
plotted against expected concentrations for all five target compounds with varying concentration ranges 
including 0.25 to 1000 ng/mL serum, 0.5 to 1000 ng/mL serum, 1 to 1000 ng/mL serum, 2 to 1000 ng/mL 
serum, 2 to 500 ng/mL serum, 1 to 500 ng/mL serum, 0.5 to 500 ng/mL serum, and 0.25 to 500 ng/mL 
serum.  For all five target compounds, the widest concentration range over which acceptable linearity was 
maintained was between 0.25 ng/mL serum and 500 ng/mL serum. No weighting factor was applied to the 
linearity study. Figure 16 shows cortisol linear response between 0.25 and 500 ng/mL serum. Figure 17 
shows 21-DOC linear response between 0.25 and 500 ng/mL serum. Figure 18 shows 11-DOC linear 
response between 0.25 and 500 ng/mL serum. Figure 19 shows 17-OHP linear response between 0.25 and 
500 ng/mL serum. Figure 20 shows 4-AD linear response between 0.25 and 500 ng/mL serum. 
 
Figure 16. Linearity plot for cortisol of enriched vs. calculated concentration for DBS analysis using internal calibration. Linear fit 
equation: y = 0.91x + 0.72; R2 = 0.9979 
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Figure 17. Linearity plot for 21-DOC of enriched vs. calculated concentration for DBS analysis using internal calibration. Linear fit 
equation: y = 0.83x + 0.25; R2 = 0.9986 
 
 
Figure 18. Linearity plot for 11-DOC of enriched vs. calculated concentration for DBS analysis using internal calibration. Linear fit 
equation: y = 1.39x + 0.84; R2 = 0.9981 
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Figure 19. Linearity plot for 17-OHP of enriched vs. calculated concentration for DBS analysis using internal calibration. Linear fit 
equation: y = 0.66x + 0.73; R2 = 0.9968 
 
Figure 20. Linearity plot for 4-AD of enriched vs. calculated concentration for DBS analysis using internal calibration. Linear fit 
equation: y = 0.70x + 0.77; R2 = 0.9962 
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Lower limit of quantitation (LOQ) was determined for each of the five target analytes by 
evaluating replicate analyses of dried blood spot extracts with concentrations as low as 0.25 ng/mL 
serum and by using two criteria. The signal-to-noise ratio (S/N) of each analyte peak and coefficient of 
variation (CV) for internal calibration concentration calculations of replicates were used to determine 
the LOQ for each analyte. The LOQ for each analyte was determined as the lowest concentration at 
which replicate analyses yielded a signal-to-noise ratio > 10:1 and CV < 20%.  
 
Figure 21. Coefficients of variation for cortisol for replicate analyses of DBS extracts. 
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Figure 22. Coefficients of variation for 21-DOC for replicate analyses of DBS extracts. 
 
 
Figure 23. Coefficients of variation for 11-DOC for replicate analyses of DBS extracts. 
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Figure 24. Coefficients of variation for 17-OHP for replicate analyses of DBS extracts. 
 
 
Figure 25. Coefficients of variation for 4-AD for replicate analyses of DBS extracts. 
 
LOQ determinations using both S/N and CV criteria are summarized in Table 15. Based upon 
LOQ findings as well as the concentration range over which all five target compounds showed 
acceptable linearity, and in order to utilize identical calibrators for all five compounds, calibration curves 
consisting of DBS enriched with concentrations ranging between 2 to 500 ng/mL serum were used for 
0
10
20
30
40
50
60
70
80
0.1 1 10 100 1000
%
 C
V
Level (ng/mL serum)
17-OHP CVs
0
10
20
30
40
50
60
0.1 1 10 100 1000
%
 C
V
Level (ng/mL serum)
4-AD CVs
 66 
subsequent analyses. A weighting factor of 1/x was used for generation of calibration curves for patient 
sample analysis. 
Table 15. LOQ determinations based upon signal-to-noise ratio and reproducibility of replicates. 
 Lower Limit of Quantitation (LOQ), ng/mL serum 
Analyte Signal-to-Noise > 10:1 CV < 20% 
CORT 2.00 2.00 
21-DOC 2.00 2.00 
11-DOC 0.50 1.00 
17-OHP 1.00 1.00 
4-AD 0.50 2.00 
 
 
4.5 HPLC column batch-to-batch reproducibility  
 
 Six HPLC columns, two columns from each of three production lots, summarized in Table 16, 
were utilized for batch-to-batch comparison to evaluate column reproducibility and reliability.  
Table 16. Summary of columns used for HPLC column batch-to-batch reproducibility evaluation. 
Column Number Production Lot Serial Number 
1 5715-0055 H17-379453 
2 5715-0056 H17-293218 
3 5715-0057 H17-317696 
4 5715-0055 H17-379454 
5 5715-0056 H17-293219 
6 5715-0057 H17-317698 
 
 Following replicate (N = 5) analyses of an unextracted standard solution containing the five 
target analytes, five isotope-labeled internal standards, as well as corticosterone and 
deoxycorticosterone as possible isobaric interferences, metrics for peak area, retention time, peak 
width, and resolution of critical pair (11-DOC from corticosterone) were compared across column lots 
and showed excellent reproducibility across all metrics, not exceeding overall variability of 5% CV for 
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peak area, analyte retention time, or peak width (using full width at half maximum, FWHM) across all 
columns. Additionally, all six columns showed acceptable baseline resolution > 1.5 of the critical pair 
(11-DOC and corticosterone). 
 Additionally, extracts of DBS QC material were pooled and then replicates (N = 5) were analyzed 
using each HPLC column. It should be noted that, while the calculated concentrations for the column 
with serial number H17-379453 were comparable to the other columns in the study, the pooled DBS 
extraction volume ran low when testing this column, therefore the DBS QC data from this column are 
potentially unreliable and were excluded from comparison analysis. Comparison metrics from the 
pooled DBS extracts were acceptable across the remaining five columns in the study. 
Because acceptable retention, resolution, and reproducibility were observed across and within 
production lots, using both analytical standards as well as pooled DBS extracts, the NBS laboratory is 
able to predict with high confidence that the assay should continue to perform in a reproducible manner 
as HPLC columns are periodically replaced. 
 
4.6 Recovery 
 
 Analyte recoveries were determined through replicate (N=10) analyses of DBS QC materials 
provided by the CDC NSQAP. Internal calibration was performed using Equation 2 to obtain calculated 
concentrations for each analyte within the specimen without influence from a calibration curve. 
Recoveries are summarized in Table 17. 
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Table 17. Analyte recoveries. 
  Recovery (%) 
Sample Enrichment (ng/mL serum) CORT 21-DOC 11-DOC 17-OHP 4-AD 
C1811 50 107 76 153 71 76 
D1811 100 101 78 151 74 76 
E1811 500 110 80 151 72 77 
 
 Analyte recoveries for CORT, 21-DOC, and 4-AD were within + 25% of the reported enrichment 
level. 17-OHP recoveries were slightly lower, between 71% and 74%, though the recoveries are consistent 
across all concentration levels. Recoveries below 100% are likely due to failure to fully elute the analyte 
from the filter paper of the dried blood spot matrix during the extraction process. The recoveries for 11-
DOC are much higher (>150%), however they are consistent across all concentration levels. It is unknown 
at this time why the recovery for 11-DOC was so high, however the use of matrix-matched dried blood 
spot calibration curves for quantitation of patient specimens corrects for high or low recoveries of each 
analyte as is indicated by the method accuracy data presented in section 4.7. It should be noted that an 
additional QC sample from CDC NSQAP, B1811, was analyzed, however data from the B1811 level were 
excluded from recovery analysis because the concentration values obtained by the NBS laboratory, as well 
as the consensus mean reported to the CDC from other laboratories, were far lower than the reported 
enrichment level for cortisol. 
 
4.7 Accuracy and precision 
 
Accuracy was evaluated using calculated QC concentration relative to the established mean 
concentration for each QC level. Concentrations were calculated using internal standard DBS calibration 
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curves. The low and high analyte recoveries reported in section 4.6 were corrected for by use of 
calibration curves. Precision was evaluated using the coefficient of variation of replicates. Inter-run 
accuracy and precision were evaluated using results for DBS QC materials at low, medium, and high 
concentration, yielding a total of 52 replicates at each QC level. It should be noted that one additional 
analytical run was excluded from analysis for all analytes due to a high outlier for 17-OHP at the low QC 
level. Inter-run accuracy and precision are summarized in Table 18 and Table 19, respectively. Intra-run 
precision and accuracy were evaluated using 25 replicates of each QC level within a single analytical run. 
Intra-run accuracy and precision are summarized in Table 18 and Table 20, respectively. 
 
Table 18. Inter- and intra-run accuracy. 
Inter- and Intra-run Accuracy (%) 
Analyte 
QC Low (8 ng/mL serum 
enrichment) 
QC Medium (40 ng/mL 
serum enrichment) 
QC High (200 ng/mL 
serum enrichment) 
Inter-run  
(N=52) 
Intra-run  
(N=25) 
Inter-run  
(N=52) 
Intra-run  
(N=25) 
Inter-run  
(N=52) 
Intra-run  
(N=25) 
CORT 103 99 97 102 102 97 
21-DOC 98 102 94 100 100 99 
11-DOC 99 106 95 98 100 94 
17-OHP 99 101 93 102 98 99 
4-AD 97 103 96 104 100 101 
 
Table 19. Inter-run precision. 
Inter-run Precision (N=52) 
Analyte 
QC Low (ng/mL serum) QC Med (ng/mL serum) QC High (ng/mL serum) 
Mean SD %CV Mean SD %CV Mean SD %CV 
CORT 10.93 0.80 7.34 47.4 2.2 4.63 258 11 4.33 
21-DOC 8.4 1.0 12.3 40.7 2.0 4.97 226 10 4.45 
11-DOC 8.81 0.76 8.64 44.0 1.9 4.24 238 10 4.11 
17-OHP 9.55 0.70 7.36 47.2 2.3 4.82 253 10 4.04 
4-AD 9.34 0.67 7.14 47.0 1.9 4.08 253 11 4.44 
 
 70 
Table 20. Intra-run precision. 
Intra-run Precision (N=25) 
Analyte 
QC Low (ng/mL serum) QC Med (ng/mL serum) QC High (ng/mL serum) 
Mean SD %CV Mean SD %CV Mean SD %CV 
CORT 10.90 0.55 5.08 48.2 2.5 5.10 250 11 4.53 
21-DOC 8.48 0.87 10.2 41.1 2.0 4.97 222 10 4.51 
11-DOC 9.46 0.63 6.62 43.9 1.8 4.17 227.8 7.5 3.31 
17-OHP 9.82 0.46 4.70 48.5 2.5 5.07 248.9 9.3 3.74 
4-AD 9.55 0.42 4.43 48.8 1.9 3.99 254.7 8.6 3.38 
 
The method showed acceptable inter- and intra-run accuracy, well within 100 + 20% for all 
analytes. Inter-run precision was acceptable as all analytes were below 20% CV for replicates. Similarly, 
intra-run precision was acceptable for all analytes, as CV of replicates was below 15% in all cases. 
 
4.8 Extract stability 
 
DBS extracts showed acceptable reproducibility for calculated concentration, at less than 20% 
CV for all analytes at one, two, and seven days post-extraction, whether stored under refrigeration or at 
room conditions. It should be noted, however, that both plates tested at seven days post-extraction 
required reconstitution prior to analysis due to evaporative loss. For this reason, the storage of plates 
for later analysis is not recommended beyond two days post-extraction. 
 
4.9 Ruggedness 
 
 As many variable factors were introduced into the validation study as were practical. Three 
analysts performed extractions, instrument analysis and data review throughout the validation. 
Precision, accuracy, and clinical sensitivity/specificity analyses were performed over a period of 16 days, 
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by three analysts, with no more than two assays with two QC replicates each being run on any given 
day. Multiple lots of the various solvents and HPLC columns were utilized throughout the validation 
study. Mobile phase and DBS extraction solution preparations were performed by multiple analysts 
throughout the study. As evidenced by the precision and accuracy data, the proposed method performs 
consistently and is sufficiently rugged given reasonable variation among factors such as personnel and 
consumable reagents. 
 
4.10 Clinical sensitivity and specificity 
 
A cohort of 344 double-blinded de-identified DBS specimens previously analyzed and reported 
by Virginia’s Newborn Screening Laboratory using the 1st tier time-resolved immunofluorescence assay 
for 17-OHP, were analyzed using the 2nd tier LC-MS/MS assay over a period of 16 days, comprising 27 
analytical runs, using three different analysts. The original results for each sample and clinical status of 
each patient were unknown to the analysts during analysis and interpretation against the provisional 
cutoff algorithm. The cohort of de-identified DBS specimens included samples from individuals 
diagnosed with various forms of CAH, samples shown to produce false positive 17-OHP results by time-
resolved immunofluorescence (including samples reported as critical, abnormal, or unsatisfactory), and 
samples that were within normal limits for 17-OHP by time-resolved immunofluorescence. Samples 
were considered to be false positive for 17-OHP by time-resolved immunofluorescence if a subsequent 
sample from the same patient was analyzed by the Newborn Screening Laboratory and found to be 
within normal limits for 17-OHP by time-resolved immunofluorescence. Where possible, the first 
specimen from each patient was analyzed in order to evaluate how the 2nd tier assay would perform 
based on the original specimen received by the laboratory. Clinical sensitivity was assessed by evaluating 
the effectiveness of the 2nd tier LC-MS/MS assay at identifying cases of various forms of CAH. Clinical 
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specificity was assessed by determining the effectiveness of the 2nd tier LC-MS/MS assay at reducing 
false positive results compared with 17-OHP analysis by time-resolved immunofluorescence alone. A 
summary of the 1st tier screening outcomes for the de-identified patient specimens analyzed for the 
validation study are included in Table 21. 
 
Table 21. 1st tier screening outcomes for de-identified DBS analyzed during method validation study. 
Sample Type Number of Specimens Comment 
True Positive 16 
9 x Salt Wasting (SW) CAH  
2 x Simple Virilizing (SV) CAH  
5 x Non-classic (NC) CAH 
False Positive 118 
1st tier 17-OHP Interpretations: 
13 x Criticala 
67 x Abnormalb 
38 x UNSATc 
True Negative 210  
Total 344  
a Critical interpretation triggers immediate referral for follow-up evaluation and diagnostic testing 
b Abnormal interpretation triggers request for a repeat DBS specimen to be collected for confirmatory analysis by the  
  NBS laboratory 
c UNSAT (unsatisfactory) interpretation indicates that valid results were unable to be obtained and a repeat DBS  
  specimen is requested by the NBS laboratory 
 
 The provisional cutoff algorithm used for the validation study is provided in Table 22. Per the 
provisional validation cutoff algorithm, 17-OHP concentration was evaluated in conjunction with the 
clinical ratio: ([17-OHP] + [4-AD]) / [CORT], which can serve to greatly reduce the number of false 
positive results reported based upon elevated 17-OHP alone.28,29,32,33 Additionally, the algorithm 
incorporates a mechanism for referring, as critical, samples that show a markedly elevated clinical ratio, 
regardless of 17-OHP concentration. This mechanism may act as a safeguard for 2nd tier analysis of DBS 
specimens from individuals with CAH that received steroid treatment prior to collection of the DBS 
specimen.32 
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Table 22. Provisional cutoff algorithm used for 2nd tier LC-MS/MS assay validation study. 
Analyte Abnormal Cutoff 
(Request Repeat 
Specimen) 
Critical Cutoff 
(Immediate referral 
to Follow-up) 
Comments 
Clinical Ratio: ([17-
OHP] + [4-AD]) / 
[CORT] 
1.00* 3.50 Ratio above abnormal 
cutoff only reported 
as positive when 17-
OHP is >= 12.00 ng/mL 
serum. Ratio above 
critical cutoff reported 
regardless of 17-OHP 
concentration 
17-OHP  N/A 12.00 ng/mL serum* 17-OHP above cutoff 
is only reported as 
positive when ratio is 
>= 1.00 
21-DOC 6.00 ng/mL serum 12.00 ng/mL serum  
11-DOC 6.00 ng/mL serum 12.00 ng/mL serum  
* Group critical ONLY when ratio is >= 1.00 AND 17-OHP is >= 12.00 
 
  
Of the 344 double-blinded patient specimens analyzed, 210 had previously screened as within 
normal limits by the 1st tier 17-OHP assay, 118 were reported as false positive by the 1st tier 17-OHP assay 
(including critical, abnormal, and unsatisfactory), and 16 samples were from individuals diagnosed with 
various forms of CAH. Of the 16 samples from individuals diagnosed with various forms of CAH, nine 
specimens were from patients diagnosed with the most severe, classic salt-wasting form of CAH, five 
specimens were from patients diagnosed with a less severe later onset, non-classic form of CAH, and two 
specimens were from patients diagnosed with the moderate simple virilizing form of CAH. It should be 
noted that one specimen from a diagnosed case of CAH was originally thought to be associated with a 
diagnosis of simple-virilizing CAH during the blinded validation study, however, was determined to be a 
non-classic CAH diagnosis after completion of the validation study.  
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 From the cohort of 210 patient specimens that previously screened as within normal limits by the 
1st tier assay, 208 were interpreted as within normal limits by the 2nd tier assay. Two specimens were 
deemed to be unsatisfactory due to inconsistent results by the 2nd tier assay, requiring a request for repeat 
NBS specimens, therefore these two results are classified as false positives by 2nd tier. 
 From the cohort of 118 patient specimens that were shown to be false positives by the 1st tier 
assay, meaning that a subsequent specimen from each patient was received and analyzed by the 1st tier 
assay and was found to be within normal limits, 88 specimens were deemed to be within normal limits by 
the 2nd tier assay. 30 specimens remained as false positives by the 2nd tier assay based upon the provisional 
validation cutoff algorithm. Of these 30 remaining false positives, 26 were deemed to be abnormal or 
critical based solely upon results obtained for the 11-DOC analyte. Four of the remaining false positives 
exhibited results similar to those expected for severe CAH cases, showing elevated 17-OHP with an 
elevated clinical ratio ([17-OHP] + [4-AD]) / [CORT] and therefore remained as false positives. All four 
specimens were collected from premature infants. 
 From the cohort of 16 patient specimens from individuals diagnosed with various forms of 21-
hydroxylase CAH, eight of nine specimens from severe classic salt-wasting cases of CAH were identified as 
critical by the provisional cutoff algorithm. One of five cases of later onset, non-classic CAH was identified 
as critical by the provisional cutoff algorithm. One of two cases of moderate simple-virilizing CAH was 
identified as critical by the provisional cutoff algorithm.   
Without adjustment, the provisional cutoff algorithm used for the validation resulted in greater 
than 70% net reduction in false positive results for CAH screening. The provisional cutoff algorithm was 
sufficient to identify most cases of salt-wasting CAH, however, most notably, the provisional cutoff scheme 
failed to identify one salt-wasting case of CAH, failed to identify one simple-virilizing case of CAH, and 
resulted in a larger than expected number of false positive results due solely to the 11-DOC cutoffs. Based  
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on these findings, adjustments to the cutoff algorithm were proposed that would ensure 100% sensitivity 
for all salt-wasting and simple-virilizing CAH cases and raise the 11-DOC cutoffs to avoid unnecessary false 
positive results based solely upon the 11-DOC analyte. The 17-OHP and clinical ratio critical cutoffs were 
lowered to 8.00 ng/mL serum and 2.00, respectively. The 11-DOC analyte is meant to be indicative of cases 
of CAH caused by 11β-hydroxylase deficiency, however, the cohort of DBS specimens analyzed for the 
validation study did not include any known cases of CAH caused by 11β-hydroxylase deficiency. All 
instances of elevated 11-DOC in the validation study are presumed to be false positives. Therefore, 
percentiles were calculated in order to adjust the 11-DOC cutoffs to further limit the number of 
reported false positive results while remaining at a conservative level to avoid missing potential true 
cases of CAH due to 11β-hydroxylase deficiency. The 11-DOC abnormal and critical cutoffs were raised 
to 20.50 ng/mL serum and 28.42 ng/mL serum, respectively. These adjusted 11-DOC cutoff values 
represent the 99.5 and 99.9 percentiles, respectively and remain well below 11-DOC concentrations 
detected in newborn screening specimens from diagnosed cases of CAH due to 11β-hydroxylase 
deficiency reported in the literature.24,31 The proposed adjustments to the cutoff algorithm are depicted 
in Table 23. 
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Table 23. Proposed go-live cutoff algorithm. 
Analyte Abnormal Cutoff 
(Request Repeat 
Specimen) 
Critical Cutoff 
(Immediate referral 
to Follow-up) 
Comments 
Clinical Ratio: ([17-
OHP] + [4-AD]) / 
[CORT] 
1.00* 2.00 Ratio above abnormal 
cutoff only reported 
as positive when 17-
OHP is >= 8.00 ng/mL 
serum. Ratio above 
critical cutoff is 
reported regardless of 
17-OHP concentration 
17-OHP  N/A 8.00 ng/mL serum* 17-OHP above cutoff 
is only reported as 
positive when ratio is 
>= 1.00 
21-DOC 6.00 ng/mL serum 12.00 ng/mL serum  
11-DOC 20.50 ng/mL serum 28.42 ng/mL serum  
* Group critical when ratio is >= 1.00 AND 17-OHP is >= 8.00 ng/mL serum 
 
 Re-evaluation of de-identified specimen results against the proposed cutoff algorithm yielded a 
greater than 90% net reduction in false positive results for CAH screening, while maintaining 100% 
sensitivity to salt-wasting and simple-virilizing CAH. The false positive results that remained based upon 
the updated algorithm were all from specimens collected from premature infants. 
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CHAPTER 5: CONCLUSIONS 
 
 
 An HPLC-MS/MS assay for 2nd tier dried blood spot screening of CAH was developed, optimized, 
and validated for a concentration range of 2 to 500 ng/mL serum. The method showed acceptable 
results for precision, accuracy, linearity, and ruggedness. The proven batch-to-batch reproducibility of 
HPLC columns provides assurance that data will remain consistent, even as columns are replaced. The 
incorporation of a reversed-phase chromatographic method utilizing an HPLC column with a superficially 
porous stationary phase support and a biphenyl stationary phase ligand enabled crucial baseline 
resolution of isobaric compounds, while allowing for rapid separation (5 minutes injection-to-injection) 
without the need for ultra-high pressure liquid chromatography (UHPLC) equipment. These 
chromatographic parameters offer significant improvement over other HPLC methods reported in the 
literature and are more readily adaptable to existing technologies within many newborn screening 
laboratories. A comparison of pros and cons of both the immunoassay-only (1-tier) algorithm as 
compared to the new 2-tier approach are summarized in Table 24. 
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Table 24. Pro-Con comparison of 1-tier vs. 2-tier approached to CAH screening 
CAH Screening Workflow Pro Con 
1-tier, immunoassay-only, with 
birthweight-adjusted cutoffs 
• Rapid: ~3.5 hr to process full 
96 well plate 
• Simple 
• Semi-automated 
• Inexpensive 
 
• High false-positive rate (~2% 
of specimens tested) 
• Limited information: 17-OHP 
only 
 
2-tier, immunoassay for 17-
OHP followed by HPLC-MS/MS 
steroid panel 
• Significantly reduces false-
positive reporting rate 
• More comprehensive: more 
information to physicians 
• Meets target turn-around 
times 
• Eliminate need for 
birthweight-adjusted cutoffs 
• More expensive per sample 
• Slower: ~10.5 hr to process 
full 96 well plate 
• Complex data review 
• Unable to eliminate all false 
positives 
 
The 2nd tier assay showed greatly improved clinical specificity when compared to the 1st tier 
time-resolved immunofluorescence assay for 17-OHP alone and is projected to significantly reduce the 
false positive rate for CAH screening. Based upon the cohort of DBS specimens analyzed as part of the 
clinical sensitivity and specificity study, there were only eight false positive specimens using the updated 
2nd tier CAH cutoff algorithm compared to 118 false positives (critical, abnormal, or unsatisfactory 
designations) from the same cohort of DBS specimens using only the immunoassay for 17-OHP, even 
when utilizing birthweight-adjusted cutoffs. This represents greater than 90% reduction in total false 
positives from the study. Based upon the analysis of de-identified DBS specimens from newborns 
diagnosed with various forms of CAH using the provisional cutoff algorithm for method validation, the 
2nd tier assay showed clinical sensitivity for most cases (eight of nine) of the most severe classic salt-
wasting form of CAH. Proposed updates and improvements to the cutoff algorithm will ensure 100% 
sensitivity for classic salt-wasting and simple-virilizing CAH for this group of specimens. The 2nd tier assay 
is not predicted to achieve 100% sensitivity for less severe non-classic form of CAH. Similar outcomes 
are documented in the literature.29,48,49 
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Under the proposed workflow to incorporate the validated 2nd tier LC-MS/MS assay into CAH 
screening, the NBS laboratory will eliminate confirmation testing, in duplicate, by the 1st tier assay. 
Instead, any specimens showing elevated 17-OHP by 1st tier fluorescence immunoassay will be 
forwarded directly to the 2nd tier analysis. The NBS laboratory will, therefore, analyze a higher 
proportion of samples per year by the 2nd tier assay than other NBS programs which employ 2nd tier 
assays for CAH screening, however, the laboratory will be better positioned to maintain an approximate 
two-day turnaround time for CAH screening results. This anticipated turnaround time will enable the 
laboratory to continue to report time-critical CAH results within nationally recommended guidelines.6 
Several parallel endeavors beyond method development and validation were initiated in order 
to move toward full implementation of 2nd tier CAH screening within Virginia’s Newborn Screening 
Laboratory. One effort included coordination with software developers for design and testing of 
laboratory information management system integration for sample tracking, resulting, and reporting of 
the 2nd tier CAH screening workflow. Additionally, input and feedback were solicited from pediatric 
endocrinologists on the screening workflow and cutoff algorithm to ensure that the 2nd tier assay will 
meet program goals without detrimental impacts to the screening process and clinical outcomes. A 
cohort of additional laboratory personnel were trained to perform the assay in order to allow for 7 day-
per-week, 365 day-per-year operation. A second LC-MS/MS instrument is also being validated to serve 
in a backup capacity to ensure that 2nd tier analysis is able to be performed each day, even if the primary 
instrument is down for maintenance or repairs.  
The 2nd tier CAH screening assay was moved into production by the Virginia NBS program on 
October 2, 2019. During the first month of testing, out of 8993 samples received for NBS analysis, 570 
samples were analyzed by the 2nd tier CAH screening method. Of the 570 samples analyzed by the 2nd 
tier CAH screening method, 23 were reported as critical and were referred to the Virginia Department of 
Health for follow up. Four samples were reported as abnormal prompting request of an additional DBS 
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specimen. A total of nine samples were deemed unsatisfactory due to lack of adequate sample quantity 
or inconsistent analytical results and an additional DBS specimen was requested. The remaining 534 
specimens were deemed to be within normal limits by the 2nd tier assay. One case whose DBS sample 
was identified as critical by the 2nd tier assay received a diagnosis of the classic salt-wasting form of CAH. 
Nine samples reported as critical or abnormal by the 2nd tier assay have received a subsequent sample 
from the same infant that was within normal limits by the 2nd tier assay, indicating that the critical or 
abnormal results reported for the original samples were likely false positive. Outcomes for the 
remaining critical or abnormal specimens are pending. 
Following full implementation of the 2nd tier CAH screening assay, continual monitoring of 
screening outcomes will help to inform quality improvement activities as well as any necessary changes 
to the assay workflow or cutoff algorithm in order to achieve the greatest possible reduction to the false 
positive reporting rate for CAH screening, while avoiding missed cases of salt-wasting or simple-virilizing 
CAH.  
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Duties: Responsible for investigation, optimization, validation, and implementation of dried blood spot 
screening and confirmatory assays for the detection of metabolic and endocrine disorders in neonates. 
Evaluation, validation, and implementation of FDA-cleared kit for dried blood spot screening for 
lysosomal storage disorders. Work with IT development teams to establish requirements for integration 
of screening assays into Laboratory Information Management System and perform user acceptance 
testing prior to implementation. LC-MS/MS technical leader, responsible for evaluation and validation of 
new instrumentation, training of personnel, and continual quality improvement. Write technical reports 
and standard operating procedures.  
 
Job Title: Scientist II – Scientist Senior, Chemical Terrorism Response and Preparedness Laboratory, 
2010-2015 
Location: Virginia Division of Consolidated Laboratory Services, Richmond VA 
Duties: Responsible for quantitative analysis using LC-MS/MS, GC-MS, and ICP-MS for clinical and 
environmental specimens. Maintained chain-of-custody for evidentiary samples. Performed individual 
and collaborative method development, optimization, and validation projects and worked with grant 
lead to coordinate projects for other scientists. Technical leader responsible for review and 
interpretation of quantitative analytical data and training of laboratory personnel. Trained first 
responders statewide regarding proper sample collection, chain-of-custody procedures, and laboratory 
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response capabilities. Wrote and reviewed technical standard operating procedures. Responsible for 
review of QA/QC data and procedures. 
 
Job Title: Scientist I, Chemical Terrorism Response and Preparedness Laboratory, 2006-2010 
Location: Virginia Division of Consolidated Laboratory Services, Richmond VA 
Duties: Responsible for quantitative analysis using LC-MS/MS and GC-MS for clinical and environmental 
specimens. Maintained chain-of-custody for evidentiary samples. Assisted with development and 
implementation of automated 96-well plate extraction protocols. Maintained stockpile of laboratory 
consumables for coverage during emergency surge capacity events. Oversaw preparation and 
distribution of Environmental Crimes Task Force field sampling kits to first responders. Trained first 
responders statewide regarding proper sample collection, chain-of-custody procedures, and laboratory 
response capabilities. 
 
Job Title: Contractor (Kelly Scientific), Chemical Terrorism Response and Preparedness Laboratory, 2005-
2006 
Location: Virginia Division of Consolidated Laboratory Services, Richmond VA 
Duties: Responsible for supply ordering, assembly, quality checks, and shipment of Environmental 
Crimes Task Force field sampling kits to first responders. Maintained database of all chain-of-custody 
evidentiary samples analyzed by the laboratory group. Completed training for one method utilizing LC-
MS/MS analysis of clinical specimens. Received training and performed analysis of unknown 
environmental specimens using GC-MS. 
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